



# HHS Public Access

Author manuscript

*Mol Cell*. Author manuscript; available in PMC 2022 February 18.

Published in final edited form as:

*Mol Cell*. 2021 February 18; 81(4): 724–738.e9. doi:10.1016/j.molcel.2020.12.037.

## ER-directed TREX1 limits cGAS activation at micronuclei

Lisa Mohr<sup>1</sup>, Eléonore Toufektchan<sup>1</sup>, Patrick von Morgen<sup>1</sup>, Kevan Chu<sup>1</sup>, Aakanksha Kapoor<sup>1</sup>, John Maciejowski<sup>1,\*</sup>

<sup>1</sup>Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

### Summary

Micronuclei are aberrant nuclear compartments that can form as a result of chromosome mis-segregation. Frequent loss of micronuclear envelope integrity exposes DNA to the cytoplasm, leading to chromosome fragmentation and immune activation. Here, we use micronuclei purification to show that the endoplasmic reticulum (ER)-associated nuclease TREX1 inhibits cGAS activation at micronuclei by degrading micronuclear DNA upon micronuclear envelope rupture. We demonstrate that the ER accesses ruptured micronuclei and plays a critical role in enabling TREX1 nucleolytic attack. *TREX1* mutations, previously implicated in immune disease, that untether TREX1 from the ER disrupt TREX1 localization to micronuclei, alleviate micronuclear DNA damage, and enhance cGAS activation. These results establish ER-directed resection of micronuclear DNA by TREX1 as a critical regulator of cytosolic DNA sensing in chromosomally unstable cells and provide a mechanistic basis for the importance of TREX1 ER-tethering in preventing autoimmunity.

### Graphical Abstract

---

\*Corresponding author and lead contact: John Maciejowski, PhD, Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, maciejoj@mskcc.org, 212.639.8581.


Author Contributions

L.M., E.T., and J.M. designed the experiments. J.M. wrote the manuscript with input from all authors. L.M. performed most experiments with help of K.C., P.v.M. and A.K.. E.T. performed experiments related to MN purification.

Declaration of interests

J.M. has received consulting fees from Ono Pharmaceutical Co.. His spouse is an employee of and has equity in Bristol Myers Squibb.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## eTOC Blurp

The ER-associated nuclease TREX1 guards against immune disease by clearing immunostimulatory DNA from the cytosol. Mohr et al. identify a key role for the ER in limiting immune activation by directing TREX1 engagement with DNA substrates such as micronuclei.

## Keywords

chromosome instability; micronuclei; nuclear envelope; cGAS; TREX1; STING; chromothripsis; endoplasmic reticulum

## Introduction

The nuclear envelope (NE) consists of a double membrane bilayer that surrounds the genome and regulates access to DNA. Challenges to NE integrity, such as mechanical compression or defects in the nuclear lamina, can cause NE rupturing and loss of nuclear compartmentalization (Maciejowski and Hatch, 2020). NE ruptures are rapidly repaired in the nucleus, but persist at aberrant, nuclear compartments, termed micronuclei (MN), that form around mis-segregated chromosomes (Hatch et al., 2013). MN with ruptured NEs (i.e. ruptured MN) exhibit defects in transcription and DNA synthesis, as well as extensive DNA damage (Crasta et al., 2012; Hatch et al., 2013). Micronuclear DNA damage is a proposed intermediate in chromothripsis, or chromosome shattering, but the initial cause(s) of damage are unknown (Crasta et al., 2012; Ly et al., 2019; Zhang et al., 2015). In addition to broad

nuclear dysfunction, ruptured MN exhibit an aberrant association with ER-derived membranes that is of unknown significance (Hatch et al., 2013; Vietri et al., 2020).

Micronuclear envelope (MNE) rupturing activates the innate immune system by enabling the cytosolic DNA sensor cGAS to be activated by chromosomal DNA (Harding et al., 2017; Mackenzie et al., 2017). Detection of double-stranded DNA (dsDNA) inside ruptured MN stimulates cGAS catalytic activity and the production of 2'3'-cyclic GMP-AMP (cGAMP) (Ablasser et al., 2013; Civril et al., 2013; Diner et al., 2013; Gao et al., 2013; Sun et al., 2013). cGAMP engages with STING, resulting in activation of the kinase TBK1 and the phosphorylation and nuclear translocation of the transcription factors IRF3 and NF- $\kappa$ B (Ishikawa and Barber, 2008; Ishikawa et al., 2009). IRF3 and NF- $\kappa$ B induce the expression of type I interferons and other immunomodulatory proteins (Ablasser and Chen, 2019). Current models of cGAS activation in ruptured MN are consistent with its biochemical preferences: cGAS recognizes dsDNA through sequence-independent interactions, but depends on long (>45 bp) dsDNA for robust activation (Civril et al., 2013; Gao et al., 2013; Sun et al., 2013). ssDNA and small dsDNA fragments do not elicit robust cGAS activity (Civril et al., 2013; Kranzusch et al., 2013; Zhou et al., 2018).

TREX1 is an ER-associated, DNA 3'→5' exonuclease that protects against chronic cGAS activation and autoimmunity by degrading cytosolic DNA (Ablasser et al., 2014; Gray et al., 2015; Grieves et al., 2015; Mazur and Perrino, 2001; Stetson et al., 2008; Wolf et al., 2016). Although it is clear that TREX1 is a key cGAS antagonist, several important questions remain. First, the mechanisms regulating TREX1 nucleolytic activity are unknown. Second, the DNA substrates that drive disease in the absence of TREX1 are poorly understood. Additionally, although TREX1 is known to associate with the ER, the functional significance of this interaction has been overlooked. Finally, frameshift mutations that eliminate TREX1's C-terminal extension are associated with systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL) (Lee-Kirsch et al., 2007; Richards et al., 2007). These mutations compromise TREX1 ER association, but do not affect its catalytic activity (Lee-Kirsch et al., 2007). Therefore, a plausible link between these mutations and potential activation of cytosolic DNA sensing pathways has remained uncertain.

Here, we show that the ER plays a key role in the regulation of cytosolic DNA sensing in chromosomally unstable cells by directing TREX1 nucleolytic activity at ruptured MN. We find that TREX1 inhibits cGAS activation at MN by accessing and degrading micronuclear DNA after MNE rupture. Surprisingly, TREX1 DNA binding function is dispensable for its accumulation in ruptured MN. Instead, we discovered that TREX1 depends on its association with the ER for access to ruptured MN. Together, our results identify TREX1 as a critical regulator of immune sensing in chromosomally unstable cells, define disease-relevant substrates of TREX1, and establish ER-tethering as a critical regulator of TREX1 nucleolytic activity.

## Results

### TREX1 inhibits cGAS activation in chromosomally unstable cells

To determine if TREX1 inhibits the activation of cytosolic DNA sensing pathways in chromosomally unstable cells, we treated wild-type and *TREX1* KO MCF10A cells with the Mps1 inhibitor reversine (Santaguida et al., 2010). Mps1 is a key component of the spindle assembly checkpoint that maintains chromosome stability during mitosis (London and Biggins, 2014). As expected, Mps1 inhibition caused frequent chromosome mis-segregations and generation of MN and DNA bridges in both wild-type and *TREX1* KO cells (Figure 1A and 1B; Figure S1A-C; Video S1). To assay cGAS activation in Mps1i-treated cells we measured cGAMP production by ELISA (Figure 1C). This analysis showed that wild-type MCF10A cells accumulated less than 20 fmol of cGAMP per million cells over 3 days of Mps1 inhibition. In contrast, *TREX1* KO cells exhibited a substantial increase in cGAMP, accumulating approximately 80–120 fmol of cGAMP per million cells. Similarly, deletion of *TREX1* in RPE1-hTERT cells overexpressing GFP-cGAS elicited strong increases in cGAMP production after Mps1i treatment (Figure S1D and S1E). As expected, *CGAS* deletion compromised cGAMP production, confirming the specificity of the assay.

We next asked if TREX1 nuclease activity was required for effective cGAS inhibition. ELISA analyses showed that *TREX1* KO cells reconstituted with the catalytically-deficient mutant GFP-TREX1-D18N (Lehtinen et al., 2008) accumulated significantly more cGAMP than *TREX1* KO cells reconstituted with wild-type GFP-TREX1 after Mps1i treatment, indicating that TREX1 nucleolytic activity is necessary to inhibit cGAS activation in chromosomally unstable cells (Figure 1D).

Following cGAS-STING activation, TBK1 phosphorylates the transcription factor IRF3 at two residues (S386 and S396), to induce IRF3 dimerization and transcription of type I IFN (Liu et al., 2015). Surprisingly, given frequent MN accumulation, IRF3 S386 phosphorylation exhibited only mild to moderate increases in wild-type MCF10A and GFP-cGAS overexpressing RPE1 cells after Mps1 inhibition (Figure 1E and 1F; Figure S1D and S1F). However, *TREX1* deletion significantly increased IRF3 S386 phosphorylation in MCF10A and RPE1 hTERT GFP-cGAS cells after Mps1 inhibition. Immunofluorescence analysis of IRF3 S396 phosphorylation showed a subtle increase in nuclear foci after Mps1 inhibition, which was significantly increased in *TREX1* KO cells (Figure 1G and 1H). Following Mps1i treatment, TREX1 protein levels were unchanged, indicating that the observed effects occurred in the absence of TREX1 upregulation (Figure 1E; Figure S1G).

In line with the lack of substantial IRF3 phosphorylation, Mps1 inhibition elicited a mild transcriptional response in wild-type MCF10A cells (Figure 1I and 1J). However, expression of *IFNB1*, *ISG56*, *IFI44*, *IFIT2*, and other Interferon-Stimulated Genes (ISGs) was elevated in *TREX1* KO cells after Mps1 inhibition. Consistent with prior observations (Simpson et al., 2020), *TREX1* deletion was not sufficient to generate a major inflammatory response in untreated, chromosomally stable MCF10A cells. Deleting *CGAS* in *TREX1* KO cells abolished the observed increases in IRF3 S386 phosphorylation and gene expression,

indicating cGAS is the prime sensor active in this system (Figure 1E and 1F and 1I and 1J; Figure S1E).

To further investigate TREX1-mediated regulation of cGAS in chromosomally unstable cells, we adapted a previously described cell model of telomere crisis (Maciejowski et al., 2015). Briefly, we use doxycycline-inducible expression of a dominant negative allele of the Shelterin subunit TRF2 to generate dicentric chromosomes (Figure S1H) (van Steensel et al., 1998). *TP53* was deleted to enable cell cycle progression in the presence of telomere dysfunction (Karlseder et al., 1999). Consistent with our prior study (Maciejowski et al., 2015), dicentric chromosomes persisted through mitosis to form long DNA bridges in approximately 80% of cell divisions (Figure S1I and S1J; Video S2).

Loss of Lamin B1 and GFP-cGAS accumulation at DNA bridges indicated likely NE rupture in wild-type and *TREX1* KO cells (Figure S1K-N; Video S3). cGAMP production was not increased during telomere crisis (Figure S1O). However, *TREX1* KO cells accumulated nearly 20 fmol of cGAMP per million cells during telomere crisis, a >2-fold increase over their TREX1-proficient counterparts. Limited cGAMP production in the telomere crisis model compared to Mps1i-treated cells may reflect differences in the relative amounts of cytosolic DNA produced in these models or tension-induced disruption of B-form DNA structure at DNA bridges (Civril et al., 2013). Taken together, these data suggest that TREX1 limits cGAS activation in chromosomally unstable cells.

Increased cGAMP levels in *TREX1* KO cells could not be explained by decreased cGAS signal intensity or localization to MN or increased MN-independent, cytosolic dsDNA levels after *TREX1* deletion or Mps1 inhibition (Figure 1K and 1L; Figure S1P-S). cGAS exists in nuclear and cytosolic fractions, associating with chromatin following mitotic NE breakdown and accumulating in the cytosol during the subsequent cell cycle (Gentili et al., 2019; Volkman et al., 2019; Yang et al., 2017). We reasoned that unexpected alterations in cGAS subcellular distribution may increase cGAMP in the *TREX1* KO cells. However, cGAS exhibited similar nuclear localization in wild-type and *TREX1* KO cells (Figure S1T and S1U).

### Purification of cGAS positive MN reveals association with TREX1

To investigate how TREX1 inhibits cGAS in chromosomally unstable cells, we developed a strategy to isolate MN based on their association with cGAS. Existing methods use differential centrifugation to separate MN from primary nuclei, but cannot distinguish between distinct types of MN (Shimizu et al., 1996). Our strategy uses genetically-encoded markers and flow cytometry to isolate MN (Figure 2A). HEK293T cells were labeled with H2B-mCherry and GFP-cGAS to mark chromatin and MN (Figure 2B). GFP-cGAS is expected to localize to ruptured MN within minutes of NE disruption (Harding et al., 2017; Mackenzie et al., 2017). Indeed, nearly 100% of ruptured MN, defined by loss of an NLS-3xmCherry marker, were marked with GFP-cGAS (Figure S2A and S2B). Similarly, the protein BAF, which accumulates at sites of NE rupture (Denais et al., 2016; Halfmann et al., 2019; Raab et al., 2016; Young et al., 2020), was also enriched at GFP-cGAS marked MN (Figure S2C and S2D).

Flow cytometric analysis of the MN-containing fractions isolated following density gradient centrifugation revealed two populations that could be distinguished by distinct forward scatter and DAPI-staining intensity (Figure 2C). Image analysis of flow-purified particles identified these populations as primary nuclei and MN (Figure 2D). Further inspection of the MN population by flow cytometry revealed two populations marked by differences in GFP-cGAS signal intensity. All purified MN exhibited a similar distribution of surface area, however, the average GFP-cGAS signal intensity differed more than two-fold across the two populations (Figure 2D-F). Immunoblotting confirmed that GFP-cGAS exhibited marked changes across the two populations (Figure 2G and 2H, Figure S2E). Additionally, BAF and the ESCRT-III component CHMP2A, which localize to ruptured MN (Vietri et al., 2020; Willan et al., 2019; Young et al., 2020), were also present in the GFP-cGAS positive MN population (Figure S2E-G). Taken together, these data validate the utility of this method for purifying cGAS-positive MN and show that ruptured MN are enriched in the GFP-cGAS-positive MN population.

We reasoned that TREX1 may regulate cytosolic DNA sensing pathways in chromosomally unstable cells by inhibiting cGAS activation at MN. To investigate this, we asked whether TREX1 co-purified with MN. Immunoblotting analysis of MN purified from HEK293T cells reconstituted with 3×FLAG-TREX1 showed that TREX1 was indeed enriched in GFP-cGAS-positive MN (Figure 2G and 2H; Figure S2H). These data indicate that TREX1 associates with MN after MNE rupture.

### **TREX1 rapidly accumulates in ruptured MN**

To better understand TREX1 association with purified cGAS-positive MN, we analyzed TREX1 localization in chromosomally unstable cells. Live-cell imaging showed that GFP-TREX1, expressed in MCF10A *TREX1* KO cells, displayed perinuclear localization consistent with its ER association (Figure 3A) (Stetson et al., 2008; Wolf et al., 2016). GFP-TREX1 localized to approximately 40% of MN within 24 h of mitotic exit (Figure 3A-C, Video S4). Analysis of GFP-TREX1 in a panel of chromosomally unstable breast cancer cell lines revealed similar localization to MN (Figure S3A).

We reasoned that TREX1 may localize to MN after MNE rupture. To test this, we assayed for MNE rupture using a previously described NLS-3×mTurquoise2 marker (Vargas et al., 2012). This analysis showed that GFP-TREX1 localization to MN was coincident with MNE rupture, as measured by loss of NLS-3×mTurquoise2 from MN (Figure 3D and 3E, Video S5). In addition, analysis of MNE rupture using mTurquoise2-tagged cGAS showed that TREX1 and cGAS localize to MN with similar timing (Figure S3B and S3C, Video S6). Immunofluorescence with an anti-TREX1 antibody confirmed the presence of endogenous protein at 40%-70% of ruptured MN and less than 5% of intact MN in cancer cell lines (Figure 3F and 3G). Additionally, transgenic TREX1 was present at 70% of cGAS-positive MN in HEK293T cells (Figure S3D and S3E). GFP-TREX1 was similarly enriched on DNA bridges (Figure S3F and S3G). Based on these data, we conclude that TREX1 localizes to MN following MNE rupture.



## ER-tethering is necessary for TREX1 targeting to ruptured MN

We next sought to understand how TREX1 is targeted to ruptured MN. TREX1 possesses high affinity for ssDNA and dsDNA (Lehtinen et al., 2008; Mazur and Perrino, 2001). We therefore reasoned that TREX1 is likely attracted to MN after MNE rupture exposes micronuclear DNA to the cytosol. To test this, we monitored the localization of a mutant protein, GFP-TREX1 R128A R174A (TREX1-RA), which exhibits compromised DNA binding (Fye et al., 2011). Unexpectedly, GFP-TREX1-RA localization to MN was comparable to the wild-type protein suggesting that TREX1 DNA binding function is dispensable for its association with MN (Figure 3H-J and S3H). Indeed, deletion of the entire TREX1 nuclease domain (TREX1<sup>-N</sup>) did not affect localization to ruptured MN (Figure 3H-J). As expected, TREX1-RA and TREX1<sup>-N</sup> maintained ER localization (Figure S3I). These data suggest that the C-terminal region of TREX1 may play a role in localization to MN.

TREX1 possesses a single-pass transmembrane helix at its C-terminus that anchors the protein in the ER and positions the nuclease domain in the cytosol (Lee-Kirsch et al., 2007; Wolf et al., 2016). Deleting this C-terminal extension compromises TREX1 association with the ER but does not affect its catalytic activity (De Silva et al., 2007; Lee-Kirsch et al., 2007). We observed that the ER luminal protein Calreticulin was enriched at TREX1-positive MN (Figure 4A and 4B), suggesting that TREX1 localization to ruptured MN may depend on its ER association. Live-cell imaging of ER dynamics in HeLa and MCF10A cells expressing GFP-TREX1 and NLS-3×Turq using an RFP-KDEL transgene or an ER tracker dye showed that the ER was excluded from intact MN, but rapidly accumulated in MN upon MNE rupture (Figure 4C-F; Figure S4A-D). In rare instances we observed examples of apparent MNE repair in HeLa cells. In these events, ER tracker dye and GFP-TREX1 were co-depleted from MN as compartmentalization was restored (Figure S4E). These data indicate that TREX1 and ER membranes exhibit similar localization dynamics to ruptured MN.

To test if the ER directs TREX1 localization in chromosomally unstable cells, we deleted the C-terminal 79 residues that contain the predicted ER transmembrane domain (TMD) (TREX1<sup>-C</sup>) (Figure 4G). As previously reported (Stetson et al., 2008), GFP-TREX1<sup>-C</sup> was localized throughout the cell, indicating apparent dissociation from the ER (Figure 4H; Figure S4F and S4G). GFP-TREX1 was present at approximately 75% of ruptured MN, while GFP-TREX1<sup>-C</sup> was never present at MN, even after MNE rupture, indicating a severe defect in normal localization (Figure 4I and 4J; Figure S4G and S4H). To determine if loss of ER association could explain the TREX1<sup>-C</sup> localization defect, we re-tethered TREX1<sup>-C</sup> to the ER via fusion to the TMD of Sec61 (TREX1<sup>-C</sup>-Sec61-TMD), a component of the ER translocon (Figure 4G and S4F). Similar to GFP-TREX1, GFP-TREX1<sup>-C</sup>-Sec61-TMD localized to 75% of ruptured MN (Figure 4I and 4J). Taken together, these data show that TREX1 localization to ruptured MN is dependent on its association with the ER.

## TREX1 resects micronuclear DNA

We reasoned that TREX1 may inhibit cGAS activation by partially degrading micronuclear DNA. Indeed, RPA32 foci were visible in 40-60% of ruptured MN compared to less than 5% of intact MN in MCF10A, RPE1-hTERT, and HEK293T + 3×FLAG-TREX1 cells (Figure 5A-C; Figure S5A-D; Video S7). Deletion of *TREX1* caused nearly complete loss of RPA32 foci at ruptured MN in all three cell lines. *TREX1 CGAS* double KO cells exhibited similar defects in the levels of ssDNA, showing that the observed defects are not due to indirect consequences from increased cGAS activation. Therefore, these data demonstrate that TREX1 generates ssDNA in ruptured MN.

In a complementary approach, we monitored ssDNA in MN by quantifying 5-bromo-2'-deoxyuridine (BrdU) levels in MN under non-denaturing conditions (Figure 5D and 5E). The BrdU assay is based on the principle that incorporated BrdU cannot be detected under native conditions unless exposed by resection (Tkáč et al., 2016). This analysis showed that the frequency of BrdU-positive ruptured MN was reduced 5-fold in *TREX1* KO cells, further supporting a model of TREX1-dependent DNA resection in ruptured MN. In addition, immunoblotting of cGAS-positive MN purified from TREX1-expressing HEK293T cells showed an approximately 50-fold increase in RPA32 relative to cGAS-negative MN indicating the presence of TREX1-dependent ssDNA in cGAS-positive MN (Figure 5F and 5G). Reintroduction of wild-type TREX1, but not the catalytically deficient TREX1-D18N, into *TREX1* KO cells restored RPA32 accumulation in MN (Figure 5H and 5I, Figure S5E). Consistent with prior reports (Lehtinen et al., 2008; Maciejowski et al., 2015; Xia et al., 2018), TREX1-D18N exhibited a dominant-negative effect, significantly reducing RPA32 signal in MN.

Analysis of additional DNA damage and repair markers yielded cell type-specific results.  $\gamma$ H2AX foci were diminished in ruptured MN in *TREX1* KO and TREX1-D18N reconstituted MCF10A cells, albeit to a lesser extent than RPA32 or native BrdU foci (Figure 5J and 5K, Figure S5F and S5G). In contrast, TREX1 loss did not result in a measurable decrease in  $\gamma$ H2AX signal in ruptured MN in HEK293T or RPE1 hTERT cells or in cGAS-positive, purified MN (Figure S5H-M). RPA32 phosphorylation, which is induced in response to DNA damage (Ciccia and Elledge, 2010), showed a TREX1-dependent increase at ruptured MN in HEK293T cells, but was not increased at MN in MCF10A cells (Figure S5N-Q).

Markers of DNA damage that depend on an active DNA damage response may not be suitable to monitor DNA damage at MN, where the relevant pathways may function abnormally. To obtain a more direct measure of DNA damage, we performed Comet assays using purified MN to visualize DNA breaks (Figure 5L and 5M). This analysis showed that ruptured MN purified from TREX1-proficient HEK293T cells exhibited significantly longer tail moments when compared to MN isolated from TREX1-deficient cells or to intact MN isolated from TREX1-proficient cells. Taken together these data show that TREX1 generates ssDNA and DNA breaks in ruptured MN.



### APE1 primes TREX1 nucleolytic activity at ruptured MN

TREX1 resides in a large, ER-associated macromolecular complex together with the endonucleases NM23-H1 and APE1, which work in concert with TREX1 to degrade nuclear DNA during granzyme A-mediated cell death (Chowdhury et al., 2006; Fan et al., 2003; Yan et al., 2010). We asked if either of these nucleases play a role in the digestion of micronuclear DNA. Deletion of *NM23H1* did not affect accumulation of RPA32 foci suggesting that NM23-H1 does not cleave micronuclear DNA (data not shown). However, deletion of *APEX1* diminished RPA32 foci at ruptured MN suggesting that APE1 may prime TREX1 nucleolytic activity by nicking or cleaving micronuclear DNA (Figure 5N and 5O; Figure S5R). *APEX1* deletion did not affect  $\gamma$ H2AX labeling at ruptured MN (Figure S5S and S5T).

### ER-tethering directs TREX1 nucleolytic activity at ruptured MN

We next sought to investigate the mechanisms underlying TREX1 activity at ruptured MN. As expected, despite maintaining localization to ruptured MN, neither the TREX1-RA nor the TREX1 N mutant was capable of generating RPA32 foci at ruptured MN (Figure 5P and 5Q). To test if ER-tethering was necessary for TREX1 nucleolytic activity at ruptured MN we examined the activities of TREX1 C and TREX1 C-Sec61-TMD at ruptured MN (Figure 4G). Consistent with its inability to localize to ruptured MN, TREX1 C was unable to resect DNA in ruptured MN as measured by RPA32 accumulation. TREX1 C was also defective in generating  $\gamma$ H2AX foci in ruptured MN (Figure S6A and S6B). In contrast, introducing TREX1 C-Sec61-TMD into *TREX1* KO cells restored RPA32 and  $\gamma$ H2AX signals to nearly normal levels in ruptured MN. These results show that ER-tethering is necessary to direct TREX1 nucleolytic activity at ruptured MN.

### TREX1 ER-association is necessary for cGAS inhibition in chromosomally unstable cells

We next asked if TREX1 ER-tethering was required for cGAS inhibition at MN. Analysis of cGAS activity via cGAMP ELISA showed that Mps1-treated *TREX1* KO and *TREX1* KO cells reconstituted with TREX1 N or TREX1 C accumulated 50-60 fmol of cGAMP per million cells (Figure 6A). In contrast, *TREX1* KO cells reconstituted with full-length TREX1 or TREX1 C-Sec61-TMD accumulated 20-25 fmol of cGAMP after Mps1 inhibition (Figure 6A and S6C). These data indicate that TREX1 tethering to the ER is critical for cGAS inhibition in chromosomally unstable cells.

Gene expression analysis further highlighted a key role for TREX1 ER-tethering in the inhibition of the cGAS-STING pathway in chromosomally unstable cells (Figure 6B). Similar to our initial results, Mps1 inhibition elicited a mild transcriptional response that was further enhanced in *TREX1* KO cells. Reintroducing full length TREX1, but not TREX1 C or the nuclease deficient TREX1-D18N, into *TREX1* KO cells restored normal gene expression. These results indicate that ER-directed TREX1 localization and activity at ruptured MN is critical for inhibiting cGAS activation and the pro-inflammatory transcriptional response.

To test whether ER-tethering is required for TREX1-dependent regulation of cGAS sensing of nucleosome-free DNA, we measured cGAMP levels after transfection with plasmid DNA

or a 45 bp immune stimulatory DNA (ISD). TREX1 C-reconstituted cells behaved similarly to cells reconstituted with wild-type TREX1 accumulating approximately 300 fmol of cGAMP per million cells after plasmid DNA transfection, while *TREX1* KO cells contained nearly 600 fmol of cGAMP per million cells (Figure S6C and S6D). TREX1 C was also effective at inhibiting cGAMP accumulation after ISD transfection albeit to a lesser degree than wild-type TREX1 (Figure 6C). Restoring TREX1 C ER-tethering via fusion to the Sec61-TMD did not further diminish cGAMP production after ISD transfection. These results suggest that ER localization is dispensable for TREX1 to engage transfected dsDNA substrates. To test this more directly, we transfected cells with biotin labeled ISD and recovered biotinylated DNA protein complexes from cell lysates using streptavidin beads (Figure 6D). Consistent with prior work (Stetson et al., 2008), TREX1 was present in the recovered biotinylated DNA/protein complexes. TREX1 association with biotinylated DNA depended on its N-terminal exonuclease domain, but not its C-terminus. Taken together, these results indicate that ER-tethering is critical for TREX1 action at MN, but dispensable for TREX1 association with and degradation of transfected, nucleosome-free dsDNA.

### **RVCL and SLE-associated *TREX1* mutations disrupt ER association, micronuclear DNA degradation, and cGAS regulation**

Mutations in *TREX1* are associated with a spectrum of autoimmune and inflammatory diseases including Aicardi-Goutières Syndrome (AGS), SLE, and RVCL (Crow and Manel, 2015). Missense mutations that compromise TREX1 nucleolytic activity are predominantly associated with AGS, while frame-shift mutations that truncate the C-terminus preserve nucleolytic activity and are associated with RVCL and SLE (Yan, 2017). The mechanisms linking *TREX1* frame-shift mutations to immune disease are poorly understood and a potential link between altered subcellular localization and engagement with dsDNA substrates has not been explored.

To determine if TREX1 C-terminal frameshift mutations might affect nuclease activity in cells we reconstituted *TREX1* KO MCF10A cells with mutants previously associated with RVCL (TREX1-V235fs, -L287fs) and SLE (TREX1-D272fs, P290L, Y305C, G306A) (Lee-Kirsch et al., 2007; Richards et al., 2007; Yan, 2017) (Figure 7A; Figure S7A). In addition, we analyzed an L309\* mutant, which is predicted to delete the TREX1 ER luminal peptide while preserving the TMD. Consistent with previous reports, GFP-TREX1-V235fs and -L287fs exhibited pan-cellular localization while GFP-TREX1-D272fs was predominantly nuclear (Lee-Kirsch et al., 2007) (Figure S7B). The L309\* mutant and the P290L, Y305C, and G306A missense mutations, which map to the predicted TMD, did not affect ER localization.

Following Mps1 inhibition GFP-TREX1-V235fs and -L287fs failed to accumulate at ruptured or intact MN (Figure 7B and 7C; Figure S7C). Interestingly, GFP-TREX1-D272fs was enriched at intact MN, but undetectable at ruptured MN. The missense TMD and L309\* mutants did not affect TREX1 localization to ruptured MN. Analysis of RPA32 foci formation at intact and ruptured MN showed that, in agreement with a defect in localization to ruptured MN, GFP-TREX1-V235fs, -L287fs, and -D272fs were unable to degrade micronuclear DNA (Figure 7D). The TREX1 TMD missense mutations partially diminished

RPA32 foci formation at ruptured MN suggesting a modest defect in TREX1 engagement with micronuclear DNA. TREX1 presence in the ER lumen appeared to be dispensable for directing its nucleolytic activity as the GFP-TREX1-L309\* mutant restored RPA32 foci formation at ruptured MN. Strikingly, despite ectopic localization to intact MN, GFP-TREX1-D272fs was incapable of degrading micronuclear DNA. These results indicate that ER-tethering may play a critical role in licensing TREX1 nucleolytic activity that goes beyond enabling access to ruptured MN.

As expected, diminished TREX1 localization and nucleolytic activity at ruptured MN correlated with increased cGAS activation (Figure 7E). In contrast, GFP-TREX1-V235fs and -L287fs were nearly as effective as GFP-TREX1-wt in suppressing cGAMP production after ISD transfection (Figure 7F). GFP-TREX1-272fs was unable to restrict cGAS activation by ISD transfection, presumably because it lacked access to the transfected ISD in the cytosolic compartment. These results further confirm that the ER plays key roles in directing TREX1 localization and nucleolytic activity at ruptured MN and inhibiting cGAS activation and suggest that MN or other sources of escaped nuclear chromatin may contribute to disease etiology in carriers of *TREX1* frame-shift mutations that disrupt ER association.

## Discussion

Here, we identify the ER as a critical regulator of cytosolic DNA sensing in chromosomally unstable cells. Our data support a model, in which the ER invades ruptured MN and enables TREX1 to access and degrade micronuclear DNA. TREX1 is capable of restricting cGAS activation at MN without completely eliminating MN or dsDNA from the cytosol. Instead, TREX1 appears to target limited regions of micronuclear DNA for resection. It is tempting to speculate that TREX1 may preferentially engage the nucleosome-free DNA most likely to activate cGAS (Zierhut et al., 2019). Observations of MN in healthy tissues (Guo et al., 2019) suggest that TREX1-dependent processing of micronuclear DNA may represent an important checkpoint against autoimmunity. We further speculate that TREX1 may depend on ER-tethering to engage additional DNA substrates. Additional targets with similarity to MN may include engulfed apoptotic chromatin fragments and cytosolic chromatin fragments introduced into the cytosol during senescence (Blander, 2017; Dou et al., 2017; Glück et al., 2017).

In addition to playing a key role in the initial recruitment of TREX1 to ruptured MN, ER tethering also appears to be critical for licensing TREX1 digestion of micronuclear DNA. The TREX1-D272fs mutation positions TREX1 inside nuclei and intact MN. Nevertheless, despite access to DNA inside these compartments, TREX1-D272fs appears to be unable to exercise its nucleolytic activity. Although we do not know the specific mechanism that accounts for TREX1's dependency on ER-tethering, the distinct requirements for TREX1 action at MN and transfected DNA point towards several possibilities. First, micronuclear DNA is packaged into chromatin while the transfected DNA is nucleosome free. Since chromatin inhibits cGAS activation and TREX1 activity (Chowdhury et al., 2006; Zierhut et al., 2019), TREX1 may be uniquely dependent on ER-tethering to overcome nucleosome-mediated inhibition at MN. Second, it is possible that the ER acts as a catalytic platform that

facilitates TREX1 interaction with priming factors such as the ER-associated APE1 that may be necessary to effectively fragment or degrade longer chromosomal DNA substrates (Fan et al., 2003). Finally, transfected DNA is present at quantities that likely exceed the quantity of cytosolic micronuclear DNA. It is conceivable that these artificial quantities do not always represent suitable models of *in vivo* targets.

The mechanisms promoting TREX1-ER accumulation at ruptured MN are not clear at present. Delivery of new sheets of ER-derived membrane by cytosolic BAF is proposed to be a critical step in the repair of ruptured NEs (Halfmann et al., 2019; Young et al., 2020). BAF also recruits the ESCRT-III complex to reseal ruptured NEs (Halfmann et al., 2019). NE repair generally does not occur in MN, however, BAF and ESCRT-III localize to MN after MNE rupture (Liu et al., 2018; Vietri et al., 2020; Willan et al., 2019). Therefore, TREX1 localization to MN may depend on BAF-dependent recruitment of ER-associated membranes or remodeling of membranes by ESCRT-III.

Unlike TREX1, cGAS accumulates on MN independently of the ER. One potential mechanism to explain these differing requirements is that cGAS condensate formation (Du and Chen, 2018) creates a selective environment that impedes passive diffusion of cytosolic proteins into MN. Despite prior access to nuclear and micronuclear compartments, cGAS exhibits a striking enrichment on chromatin that is exposed to the cytosol through NE rupture. Live-cell imaging of mTurquoise2-tagged transgenic cGAS suggests that this hyper-accumulation of cGAS may draw from micronuclear or cytosolic pools of the protein. These data suggest that cGAS distinguishes between cytosol-exposed chromatin and chromatin protected within a NE compartment.

Our work has implications for understanding clustered chromosome rearrangements. MNE rupture is associated with DNA damage, chromothripsis, and the acquisition of mutation clusters termed kataegis (Crasta et al., 2012; Hatch et al., 2013; Ly et al., 2017, 2019; Umbreit et al., 2020; Zhang et al., 2015). Our report is the first to identify an enzymatic source of DNA damage in MN after MNE rupture. These findings are consistent with recent work showing that TREX1 is the primary source of the DNA damage that occurs in the primary nucleus after compression-induced NE rupture (Nader et al., 2020). Consideration of this data, together with the work presented here, suggests the existence of similar TREX1-dependent mechanisms underlying NE rupture-associated DNA damage at the primary nucleus and at MN.

Finally, our work suggests that TREX1-mediated inhibition of cGAS sensing of ruptured MN may be one mechanism that chromosomally unstable tumor cells rely on to suppress anti-tumor immunity and cell autonomous growth inhibition resulting from chronic cGAS-STING pathway activation. Therefore, TREX1-mediated DNA degradation in MN may enable cancer cells to benefit from chromosomal instability without the potentially lethal effects of cGAS-STING activation.

## Limitations

Our results argue against broad functional classification of mutations that truncate the TREX1 C-terminus and suggest a potential mechanism that may guide distinct clinical courses for these mutants. Failure to digest micronuclear DNA does not seem to be related to a proposed role for TREX1 in regulation of the ER oligosaccharyltransferase complex (Fermaint et al., 2019; Hasan et al., 2015; Kucej et al., 2017) as deletion of the small peptide of TREX1 predicted to access the ER lumen does not perturb RPA32 foci accumulation at ruptured MN (Figure 7). However, our data do not disregard a role for TREX1 in the ER lumen. Indeed, our work at present cannot explain the dominant nature of these frameshift mutations. In the future, it will be interesting to further assess how truncated fragments of TREX1 may interact with the intact protein to affect DNA engagement and nucleolytic activity and to identify DNA substrates that drive disease in the absence of TREX1.

## STAR Methods

### RESOURCE AVAILABILITY

**Lead Contact**—Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John Maciejowski (maciejoj@mskcc.org).

**Materials Availability**—Cell lines generated in this study and listed in the Key Resources Table are available from Dr. John Maciejowski. Plasmids used in this study and listed in the Key Resources Table are available on Addgene ([www.addgene.org](http://www.addgene.org)).

**Data and Code Availability**—The datasets and original source data generated during this study are available at Mendeley Data [<http://dx.doi.org/10.17632/d8p53cv3ry.1>].

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

MCF10A cells were cultured in 1:1 mixture of F12:DMEM media supplemented with 5% horse serum (Thermo Fisher Scientific), 20 ng/ml human EGF (Sigma), 0.5 mg/ml hydrocortisone (Sigma), 100 ng/ml cholera toxin (Sigma) and 10 µg/ml recombinant human insulin (Sigma). BT474 cells were cultured in RPMI 1640 supplemented with 10% FBS, 1% glucose, 1% sodium pyruvate. HCC1143 cells were cultured in RPMI 1640 supplemented with 10% FBS. RPE1-hTERT and MDA-MB-453 cells were cultured in F12:DMEM supplemented with 10% FBS. HEK293T, Phoenix, 293FT, HeLa, HT1080, CAL51, BT549, and U2OS were grown in DMEM supplemented with 10% FBS. All media was supplemented with 1% penicillin-streptomycin. Unless otherwise noted, all media and supplements were supplied by the MSKCC Media Preparation core facility.

### METHOD DETAILS

**Viral Transduction**—For retroviral transduction, open reading frames were cloned into pQCXIN, pQCXIP, pQCXIB (Clontech), or pQCXIZ, which confer resistance to G418, puromycin, blasticidin, and zeocin. Constructs were transfected into Phoenix amphotropic

packaging cells using calcium phosphate precipitation. Cell supernatants containing retrovirus were filtered, mixed 1:1 with target cell media and supplemented with 4 µg/ml polybrene. Successfully transduced cells were selected using G418 (Corning), puromycin (Fisher), blasticidin (Fisher), or zeocin (Life Technologies). Clones were isolated by limiting dilution or flow sorting.

For lentiviral transduction, open reading frames were cloned into pLenti CMV GFP Neo/Blast/Puro (Addgene). Constructs were transfected into 293FT cells together with psPAX2 and pMD2.G (Addgene) using calcium phosphate precipitation. Supernatants containing lentivirus were filtered and supplemented with 4 µg/ml polybrene. Successfully transduced cells were selected as above.

**Immunofluorescence microscopy**—For immunofluorescence microscopy of micronucleated cells, MCF10A cells, seeded on coverslips 24 h before, were treated with 0.5 µM of the Mps1 inhibitor reversine for 72 h. Parental and 3×FLAG-TREX1 overexpressing HEK293T (+H2B-mCherry +GFP-cGAS) cells, as well as RPE1 hTERT were treated for 48 h, while HeLa, RPE1 hTERT, HT10080, and U2OS cells (Figure 3F) were treated for 24h. Cells were treated with HU (2 mM) for 24 h (Figure S5P and S5Q).

For immunofluorescence staining for BAF, cGAS, Calreticulin, dsDNA, γH2AX, H3K9ac, GFP, LSD1, RPA32, pRPA32 or TREX1, cells were carefully washed with PBS prior to fixation in 2% paraformaldehyde in PBS for 12 min. For staining of pIRF3, cells were incubated with TBS-TX (TBS supplemented with 0.1% Triton X-100) for 5 min and fixed with -20° C methanol and kept at -20° C for at least 1 h. Coverslips were washed with TBS, incubated in TBS with 0.5% Triton X-100 for 5 min and washed again with TBS. Coverslips were incubated in blocking buffer (1 mg/ml BSA, 3% goat serum, 0.1% Triton X-100, 1 mM EDTA in PBS) for 1 h and primary antibodies (see Key Resources Table), diluted in blocking buffer, were added for 2 h. After 4 washes with TBS-TX, coverslips were incubated with secondary antibodies (see Key Resources Table), diluted in blocking buffer, for 1 h, then washed 2 times with TBS-TX. DNA was stained with DAPI or Hoechst (both at 1 µg/ml) for 10 min, before coverslips were washed 2 times with TBS-TX and once with TBS. Coverslips were mounted in ProLong Gold Antifade Mountant (Life Technologies). IF images shown in Figures 1,2, 3F, 4H,I, 5, S1, S3A,D, S5 (excluding S5N) and S6 were acquired on a DeltaVision Elite system equipped with a DV Elite CMOS camera, microtiter stage, and ultimate focus module (Z-stacks through the cells at 0.2 µm increments). For Figures 1G, 5P and S6A images were processed by digital deconvolution of Z-stack image series using softWoRx software. Images shown in Figures 3I, 4A, 7, S2, S3I, S5N and S7 were acquired on a Nikon Eclipse Ti2-E equipped with a CSU-W1 spinning disk with Borealis microadapter, Perfect Focus 4, motorized turret and encoded stage, polycarbonate thermal box, 5 line laser launch [405 (100 mw), 445 (45 mw), 488 (100 mw), 561 (80 mw), 640 (75 mw)], PRIME 95B Monochrome Digital Camera and 100x 1.45 NA objective. Images were further edited with Adobe Photoshop CS5.1.

For staining of cytosolic dsDNA (Figure S1P-S), cells were treated with TBS with 0.02% saponin for 5 min after fixation to selectively permeabilize the plasma membrane as previously described (Bakhom et al., 2018).



**Native BrdU staining**—For detection of ssDNA in MN, cells seeded on coverslips were preincubated with BrdU (10  $\mu$ M) for 24 h, washed twice with media and treated with reversine (0.5  $\mu$ M) for 48 h. Before BrdU and cGAS IF, cells were carefully washed with PBS, incubated in ice cold extraction buffer (10mM Pipes-NaOH pH 7, 100mM NaCl, 300mM sucrose, 3mM MgCl<sub>2</sub>, 1mM EGTA, 0.5% Triton X-100) for 10 min. Fixation and staining steps, as well as quantification were performed as described above.

**Live-cell imaging**—Cells were plated onto 35 mm glass bottom dishes (Cellvis) 48 h before imaging. Where indicated cells were treated overnight with Mps1i (reversine, 0.5  $\mu$ M) to induce MN. ER tracker (Thermo Fisher Scientific) was used at a final concentration of 1 $\mu$ M and added directly before imaging. Live-cell imaging was performed at 37° C and 5% CO<sub>2</sub> using a Nikon Eclipse Ti2-E equipped with a CSU-W1 spinning disk with Borealis microadapter, Perfect Focus 4, motorized turret and encoded stage, polycarbonate thermal box, 5 line laser launch [405 (100 mw), 445 (45 mw), 488 (100 mw), 561 (80 mw), 640 (75 mw)], PRIME 95B Monochrome Digital Camera, and environmental enclosure (Tokai Hit). Objective lenses included CFI Plan Apo Lambda 40x 0.95 NA and CI Plan Apo Lambda 60x 1.40 NA. Images were acquired using NIS-Elements Advanced Research Software on a Dual Xeon Imaging workstation. Maximum intensity projection of z-stacks and adjustment of brightness and contrast were performed using Fiji software. Images were cropped and assembled into figures using Photoshop CS5.1 (Adobe).

**MN purification**—Micronucleus purification protocol was adapted from a previously described method (Shimizu et al., 1996). Parental and 3 $\times$ FLAG-TREX1 overexpressing HEK293T (+H2B-mCherry +GFP-cGAS) cells were treated with 0.5  $\mu$ M reversine 48 h prior to harvesting.  $10^8$ - $10^9$  cells were harvested and washed twice in DMEM without serum. Washed cells were resuspended in pre-warmed (37° C) DMEM without serum supplemented with cytochalasin B (Cayman) at 10  $\mu$ g/ml at a concentration of  $10^7$  cells/ml DMEM and incubated at 37° C for 30 minutes. Cells were centrifuged at 300 x g for 5 minutes and the cell pellet was resuspended in cold lysis buffer (10 mM Tris-HCl, 2 mM Mg-acetate, 3 mM CaCl<sub>2</sub>, 0.32 M sucrose, 0.1 mM EDTA, 0.1% (v/v) NP-40, pH 8.5) freshly complemented (with 1 mM dithiothreitol, 0.15 mM spermine, 0.75 mM spermidine, 10  $\mu$ g/ml cytochalasin B and protease inhibitors) at a concentration of  $2 \times 10^7$  cells/ml lysis buffer. Resuspended cells were then dounce homogenized by 10 strokes with a loose-fitting pestle. At this point a verification step was performed by mixing a small volume of lysed cells with an equal volume of PBS + 0.5  $\mu$ g/ml DAPI to confirm MN release. Cell lysates were then mixed with an equal volume of ice cold 1.8 M sucrose buffer (10 mM Tris-HCl, 1.8 M sucrose, 5 mM Mg-acetate, 0.1 mM EDTA, pH 8.0) freshly complemented (with 1 mM dithiothreitol, 0.3% BSA, 0.15 mM spermine, 0.75 mM spermidine) before use. 10 ml of this mixture (lysed cells + 1.8 M sucrose buffer) was then layered on top of a two-layer sucrose gradient (prepared by slowly adding 20 ml of 1.8 M sucrose buffer slowly on top of 15 ml 1.6 M sucrose buffer in a 50 ml conical tube). This mixture was then centrifuged in a JS-5.2 swinging bucket rotor (Beckman) at 944 x g for 20 min at 4° C. Generally, fractions were collected as follows: upper 2 ml typically contains debris and is discarded; next 5–6 ml contains MN and is collected; final 38 ml contains primary nuclei and is discarded. At this point a verification step was often included to most accurately identify fractions containing

MN and lacking cell debris and primary nuclei. Fractions containing MN were then pooled and diluted 1:5 with FACS buffer (ice cold PBS supplemented with 0.3% BSA, 0.1% NP-40 and protease inhibitors). Diluted MN were then centrifuged at  $944 \times g$  in JS-5.2 swinging bucket rotor for 20 min at 4° C. Supernatant was then removed by aspiration and MN were resuspended in 2–4 ml of FACS buffer supplemented with 2  $\mu\text{g/ml}$  DAPI. Resuspended samples were filtered through a 40  $\mu\text{m}$  ministainer (PluriSelect) into FACS tubes. MN were then sorted by FACSaria (BD Biosciences) into FACS buffer at the MSKCC Flow Cytometry Core Facility. Default FSC and DAPI thresholds were lowered and a log scale was used to visualize MN. Sorted MN were centrifuged at  $4000 \times g$  in JS-5.2 swinging bucket rotor for 20 min at 4° C and the pellets were stored at  $-80^\circ\text{C}$  before lysis for Western blotting or used directly for immunofluorescence microscopy.

**Immunofluorescence of purified MN**—For immunofluorescence microscopy of purified micronuclei, samples were fixed in 2% paraformaldehyde for 10 minutes by adding the appropriate volume of 16% paraformaldehyde to the samples collected in FACS buffer (ice cold PBS supplemented with 0.3% BSA, 0.1% NP-40 and protease inhibitors). Then, samples were loaded in cytofunnels (Thermo Fisher), centrifuged on microscopy slides using a Cytospin 4 centrifuge (Thermo Fisher) and dried overnight at room temperature. Each sample was circled with an aqua-hold pap pen (Fisher Scientific) prior to incubation in blocking buffer, antibody and DAPI staining (see above).

**Comet Assay**—The alkaline comet assay was performed as described previously (Tice et al., 1990). Microscopic slides were covered with 1% normal agarose prepared in PBS and left to solidify overnight at room temperature. The first agarose layer was covered with  $3\text{--}5 \times 10^5$  purified MN resuspended in 10  $\mu\text{l}$  PBS mixed with 75  $\mu\text{l}$  of 1% low melting point agarose at 37°C and immediately covered with a coverslip. Slides were placed on ice to solidify the agarose. Then, a third layer of 1% low melting point agarose at 37°C was added and covered with a coverslip. After solidification on ice, positive control slides were immersed in 25  $\mu\text{M}$   $\text{KMnO}_4$  solution, to induce oxidative damage (Koizume et al., 1998; Kouzine et al., 2017) for 20 min at 4°C. Then, all the slides were immersed in the lysing solution (2.5 M NaCl, 100 mM EDTA, 10 mM TRIS, pH 10) for 2h at 4°C. The slides were then transferred to an electrophoresis solution (300 mM NaOH, 1 mM EDTA) for 20 min. Next, electrophoresis was carried out at 21 V, 300 mA for 20 min. The slides were then washed in a neutralization solution (0.4 M Tris, pH 7.5) three times for 5 min and dehydrated in 70%, 90% and 100% ethanol successively, 3 min each. Slides were left to dry for 2h at RT before staining with 2.0  $\mu\text{g/ml}$  DAPI for 20 min at RT. Finally, the slides were imaged with a DeltaVision Elite system.

**Immunoblotting**—For the Western blots shown in Figures S1C,H and S5E cells were harvested by trypsinization and lysed in  $1 \times$  Laemmli buffer (50 mM Tris, 10% glycerol, 2% SDS, 0.01% bromophenol blue, 2.5%  $\beta$ -mercaptoethanol) at  $10^7$  cells/ml. Lysates were denatured at 95° C and DNA was sheared with a 28  $\frac{1}{2}$  gauge insulin needle. Lysate equivalent to  $1\text{--}2 \times 10^5$  cells was resolved by SDS-PAGE (Life Technologies) and transferred to nitrocellulose membranes (Amersham). Membranes were blocked in 5% milk in TBS with 0.1% Tween-20 (TBS-T) and incubated with primary antibody (see Key Resources

Table) overnight at 4° C, washed 4 times in TBS-T, and incubated for 1 h at room temperature with horseradish-peroxidase-conjugated secondary antibody (see Key Resources Table). After four washes in TBS-T, membranes were rinsed in TBS and imaging was performed using enhanced chemiluminescence (Thermo Fisher).

For quantitative Western blotting (Figures 1E, S1D, S3H, S4F, S5R, S6C, S7A), cells were lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), supplemented with phosphatase inhibitors (10 mM NaF, 20 mM  $\beta$ -glycerophosphate) and protease inhibitor (Thermo Scientific) at  $\sim 10^7$  cells/ml and incubated on ice for 30 min. After centrifugation (21,000 x g, 30 min, 4°C), protein concentration of the supernatant was determined using BCA protein assay (Thermo Fisher) and 50  $\mu$ g (Figures 1E, S1D) or 20  $\mu$ g (Figures S3H, S4F, S5R, S6C, S7A) protein was loaded per sample. Membranes were blocked in Odyssey blocking buffer in TBS (Li-COR). Primary antibodies were diluted in blocking buffer supplemented with 0.2% Tween and incubated with membranes overnight at 4° C. Secondary antibodies (Alexa Fluor 680 and 800; Key Resources Table) were used at 1:20,000 dilutions in blocking buffer supplemented with 0.2% Tween. Fluorescence was measured using an infrared imaging scanner (Odyssey; LI-COR) according to the manufacturer's instructions.

For Western blots of purified micronuclei (Figures 2G, 5F, S2E,G,H and S5L), samples were lysed in 1x Laemmli buffer at  $2.5 \times 10^7$  MN/ml. Lysates were denatured at 95° C and DNA was sonicated using a Bioruptor 300 (Diagenode) on the high setting for 8 cycles 30 sec ON / 30 sec OFF. Lysate equivalents to  $0.5 \times 10^6$  micronuclei were loaded in each lane and processed as described above for quantitative Western blotting.

**Gene expression analysis**—Total RNA was isolated from  $2 \times 10^6$  cells using the Quick-RNA miniprep kit (Zymo) according to the manufacturer's instructions.

cDNA was generated from 500 ng RNA using the Superscript IV first-strand synthesis system (Life Technologies) with random hexamer priming. qPCR was performed with gene specific primers (see Key Resources Table) using Sybr green detection on a Light Cycler 480 (Roche) or Quantstudio6 (Applied Biosystems) cycler. Relative transcription levels were calculated by normalizing to ACT expression.

NanoString was used to directly quantify mRNA transcripts. Isolated RNA was hybridized with reporter and capture probes of the nCounter Human Inflammation V2 Panel (Figure 1G and S2H, see Key Resources Table) or a custom made nCounter gene expression code set (Figure 5E, see Table S1) according to the manufacturer's instructions (NanoString Technologies). Data was analyzed using nSolver Analysis software.

**2'3'-cGAMP quantification**— $4 \times 10^6$  of MCF10A or M2p1 cells were seeded into 15-cm dishes, and 24 h later cells were treated with reversine (0.5  $\mu$ M) or doxycycline (1  $\mu$ g/ml), respectively. For stimulation with ISD and dsDNA,  $1.5 \times 10^6$  of MCF10A cells were seeded into 10-cm dishes, and 24 h later transfected with 8  $\mu$ g of 45 bp ISD (Invivogen) using Lipofectamine 3000 transfection reagent (Invitrogen) or 4  $\mu$ g of pMaxGFP plasmid (Lonza) using Fugene HD transfection reagent (Promega) per manufacturer's instructions.

72 h after reversine and doxycycline addition or 24 h after transfection, cells were harvested, washed with PBS, pelleted, and stored at  $-80^{\circ}\text{C}$ . To quantify 2'3'-cGAMP levels,  $8 \times 10^6$  cells (reversine) or  $2 \times 10^6$  cells (DNA) were thoroughly resuspended in 120  $\mu\text{L}$  lysis buffer (20 mM Tris-HCl pH 7.7, 100 mM NaCl, 10 mM NaF, 20 mM  $\beta$ -glycerophosphate, 5 mM  $\text{MgCl}_2$ , 0.1% Triton X-100, 5% glycerol) and lysed with a 28  $\frac{1}{2}$  gauge needle. Lysates were incubated on ice for 30 min, centrifuged at  $16,000 \times g$ ,  $4^{\circ}\text{C}$  for 10 min and 2'3'-cGAMP levels were quantified using the 2'3'-cGAMP ELISA Kit (Arbor Assays) according to the manufacturer's instructions.

**Biotin-ISD pulldown**— $7 \times 10^6$  of MCF10A cells expressing GFP-TREX1-FL, N or C were seeded on 2 15-cm dishes for each cell line and 24 h later, cells were transfected with 18  $\mu\text{g}$  biotinylated or naked ISD (IDT, see Key Resources Table) using Lipofectamine 3000 transfection reagent (Invitrogen) per manufacturer's instructions (DNA:Lipofectamine, 1:3). 2 h after transfection, cells were harvested by trypsinization, washed with PBS and resuspended in lysis buffer (50 mM Tris pH 7.5, 200 mM NaCl, 0.075% NP-40, protease inhibitors) at  $10^7$  cells/ml. Cells were then dounce homogenized by 10 strokes with a tight-fitting pestle. Lysates were incubated on ice for 20 min, centrifuged at  $16,000 \times g$ ,  $4^{\circ}\text{C}$  for 20 min and input samples were taken for immunoblotting. To reduce non-specific binding of proteins to the beads, lysates were precleared by incubation with Protein G dynabeads (Invitrogen) for 30 min at room temperature. To pull down the biotinylated ISD, the cleared lysate was transferred onto streptavidin dynabeads (75  $\mu\text{L}$  per sample, Invitrogen) and again incubated for 30 min at room temperature. The beads were washed 8 times with lysis buffer and then eluted with  $2 \times$  Laemmli buffer (100 mM Tris, 20% glycerol, 4% SDS, 0.02% bromophenol blue, 5%  $\beta$ -mercaptoethanol).

## QUANTIFICATION AND STATISTICAL ANALYSIS

**Quantification of micronuclear DNA damage**—Quantification of RPA32-,  $\gamma\text{H2AX}$ - or BrdU-positive MN was performed as follows: After deconvolution of Z-stack image series and maximum intensity projections, MN were identified by Hoechst signal. Then the LSD1, H3K9ac, Rb or cGAS signal was used to distinguish between intact (LSD-, H3K9ac-, Rb-positive or cGAS-negative) and ruptured MN (LSD-, H3K9ac-, Rb-negative or cGAS-positive). Finally, MN were called RPA32-,  $\gamma\text{H2AX}$ - or BrdU-positive, if there were more than 2 clear foci visible per MN.

**Statistical Analysis**—Information regarding biological replicates, sample size, and statistical testing is supplied in the Figure Legends.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank T. de Lange, P. Kranzusch, W. Zhou, C. Zierhut, A. Sfeir, E. Hatch, and Z. Chen for advice and reagents, the Integrated Genomics Operation at MSKCC for assistance with Nanostring analysis, M. Piel and G. Nader for sharing unpublished data, and support from the NCI (R00CA212290), the Pew Charitable Trusts, the Starr Cancer Consortium, the Geoffrey Beene and Ludwig Centers at MSKCC, and MSKCC core grant P30-CA008748.

## References

- Ablasser A, and Chen ZJ (2019). cGAS in action: Expanding roles in immunity and inflammation. *Science* 363.
- Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, Hopfner K-P, Ludwig J, and Hornung V (2013). cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. *Nature* 498, 380–384. [PubMed: 23722158]
- Ablasser A, Hemmerling I, Schmid-Burgk JL, Behrendt R, Roers A, and Hornung V (2014). TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. *J. Immunol* 192, 5993–5997. [PubMed: 24813208]
- Bakhoun SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, et al. (2018). Chromosomal instability drives metastasis through a cytosolic DNA response. *Nature* 553, 467–472. [PubMed: 29342134]
- Blander JM (2017). The many ways tissue phagocytes respond to dying cells. *Immunol. Rev* 277, 158–173. [PubMed: 28462530]
- Carr JM, Ashander LM, Calvert JK, Ma Y, Aloia A, Bracho GG, Chee SP, Appukuttan B, and Smith JR. (2017). Molecular Responses of Human Retinal Cells to Infection with Dengue Virus. *Mediators Inflamm.* 2017, 3164375. [PubMed: 29515292]
- Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, and Kaufman PD (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. *PLoS one*, 4, e6529. [PubMed: 19657394]
- Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung J-S, Demple B, Perrino FW, and Lieberman J (2006). The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. *Mol. Cell* 23, 133–142. [PubMed: 16818237]
- Ciccia A, and Elledge SJ (2010). The DNA damage response: making it safe to play with knives. *Mol. Cell* 40, 179–204. [PubMed: 20965415]
- Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V, and Hopfner K-P (2013). Structural mechanism of cytosolic DNA sensing by cGAS. *Nature* 498, 332–337. [PubMed: 23722159]
- Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, Pan Y, Nezi L, Protopopov A, Chowdhury D, and Pellman D (2012). DNA breaks and chromosome pulverization from errors in mitosis. *Nature* 482, 53–58. [PubMed: 22258507]
- Crow YJ, and Manel N (2015). Aicardi–Goutières syndrome and the type I interferonopathies. *Nat. Rev. Immunol* 15, 429–440. [PubMed: 26052098]
- Denais CM, Gilbert RM, Isermann P, McGregor AL, te Lindert M, Weigelin B, Davidson PM, Friedl P, Wolf K, and Lammerding J (2016). Nuclear envelope rupture and repair during cancer cell migration. *Science* 352, 353–358. [PubMed: 27013428]
- De Silva U, Choudhury S, Bailey SL, Harvey S, Perrino FW, and Hollis T (2007). The crystal structure of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein partnering. *J. Biol. Chem* 282, 10537–10543. [PubMed: 17293595]
- Diner BA, Lum KK, Javitt A, and Cristea IM (2015). Interactions of the Antiviral Factor Interferon Gamma-Inducible Protein 16 (IFI16) Mediate Immune Signaling and Herpes Simplex Virus-1 Immunosuppression. *Mol. Cell. Proteomics* 14, 2341–2356. [PubMed: 25693804]
- Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, and Vance RE (2013). The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. *Cell Rep.* 3, 1355–1361. [PubMed: 23707065]
- Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangenstein KJ, Simithy J, Lan Y, Lin Y, Zhou Z, et al. (2017). Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* 550, 402–406. [PubMed: 28976970]
- Du M, and Chen ZJ (2018). DNA-induced liquid phase condensation of cGAS activates innate immune signaling. *Science* 361, 704–709. [PubMed: 29976794]



- Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, and Lieberman J (2003). Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. *Nat. Immunol* 4, 145–153. [PubMed: 12524539]
- Fermaintt CS, Sano K, Liu Z, Ishii N, Seino J, Dobbs N, Suzuki T, Fu Y-X, Lehrman MA, Matsuo I, et al. (2019). A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response. *Nat. Commun* 10, 2377. [PubMed: 31147550]
- Fye JM, Orebaugh CD, Coffin SR, and Hollis T (2011). Dominant mutations of the TREX1 exonuclease gene in lupus and Aicardi-Goutières syndrome. *J. Biol. Chem* 286, 32373–32382. [PubMed: 21808053]
- Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, Gaffney BL, Shuman S, Jones RA, Deng L, et al. (2013). Structure-function analysis of STING activation by c [G (2', 5') pA (3', 5') p] and targeting by antiviral DMXAA. *Cell* 154, 748–762. [PubMed: 23910378]
- Gentili M, Lahaye X, Nadalin F, Nader GPF, Lombardi EP, Herve S, De Silva NS, Rookhuizen DC, Zueva E, Goudot C, et al. (2019). The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. *Cell Rep.* 26, 3798. [PubMed: 30917330]
- Glück S, Guey B, Gulen MF, Wolter K, Kang T-W, Schmacke NA, Bridgeman A, Rehwinkel J, Zender L, and Ablasser A (2017). Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. *Nat. Cell Biol* 19, 1061–1070. [PubMed: 28759028]
- Gray EE, Treuting PM, Woodward JJ, and Stetson DB (2015). Cutting Edge: cGAS Is Required for Lethal Autoimmune Disease in the Trex1-Deficient Mouse Model of Aicardi–Goutières Syndrome. *The Journal of Immunology* 195, 1939–1943. [PubMed: 26223655]
- Grieves JL, Fye JM, Harvey S, Grayson JM, Hollis T, and Perrino FW (2015). Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. *Proc. Natl. Acad. Sci. U. S. A* 112, 5117–5122. [PubMed: 25848017]
- Guo X, Ni J, Liang Z, Xue J, Fenech MF, and Wang X (2019). The molecular origins and pathophysiological consequences of micronuclei: New insights into an age-old problem. *Mutat. Res* 779, 1–35. [PubMed: 31097147]
- Halfmann CT, Sears RM, Katiyar A, Busselman BW, Aman LK, Zhang Q, O'Bryan CS, Angelini TE, Lele TP, and Roux KJ (2019). Repair of nuclear ruptures requires barrier-to-autointegration factor. *J. Cell Biol* 218, 2136–2149. [PubMed: 31147383]
- Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, and Greenberg RA (2017). Mitotic progression following DNA damage enables pattern recognition within micronuclei. *Nature* 548, 466–470. [PubMed: 28759889]
- Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, Jiang S, Li Q-Z, Atkinson JP, Morse HC 3rd, Lehrman MA, et al. (2015). Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. *Immunity* 43, 463–474. [PubMed: 26320659]
- Hatch EM, Fischer AH, Deerinck TJ, and Hetzer MW (2013). Catastrophic nuclear envelope collapse in cancer cell micronuclei. *Cell* 154, 47–60. [PubMed: 23827674]
- Ishikawa H, and Barber GN (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 455, 674–678. [PubMed: 18724357]
- Ishikawa H, Ma Z, and Barber GN (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* 461, 788–792. [PubMed: 19776740]
- Karlseder J, Broccoli D, Dai Y, Hardy S, and de Lange T (1999). p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. *Science* 283, 1321–1325. [PubMed: 10037601]
- Koizume S, Inoue H, Kamiya H, and Ohtsuka E (1998). Neighboring base damage induced by permanganate oxidation of 8-oxoguanine in DNA. *Nucleic Acids Res.* 26, 3599–3607. [PubMed: 9671825]
- Kouzine F, Wojtowicz D, Baranello L, Yamane A, Nelson S, Resch W, Kieffer-Kwon K-R, Benham CJ, Casellas R, Przytycka TM, et al. (2017). Permanganate/S1 Nuclease Footprinting Reveals Non-B DNA Structures with Regulatory Potential across a Mammalian Genome. *Cell Syst* 4, 344–356.e7. [PubMed: 28237796]




- Kranzusch PJ, Lee AS-Y, Berger JM, and Doudna JA (2013). Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. *Cell Rep.* 3, 1362–1368. [PubMed: 23707061]
- Kucej M, Fermaintt CS, Yang K, Irizarry-Caro RA, and Yan N (2017). Mitotic Phosphorylation of TREX1 C Terminus Disrupts TREX1 Regulation of the Oligosaccharyltransferase Complex. *Cell Rep.* 18, 2600–2607. [PubMed: 28297665]
- Kudo T, Jekni S, Macklin DN, Akhter S, Hughey JJ, Regot S, and Covert MW (2018). Live-cell measurements of kinase activity in single cells using translocation reporters. *Nat. Protoc.* 13, 155–169. [PubMed: 29266096]
- Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee Y-A, de Silva U, Bailey SL, Witte T, Vyse TJ, et al. (2007). Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. *Nat. Genet.* 39, 1065–1067. [PubMed: 17660818]
- Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, and Perrino FW (2008). The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. *J. Biol. Chem.* 283, 31649–31656. [PubMed: 18805785]
- Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, Du F, Ren J, Wu Y-T, Grishin NV, et al. (2015). Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science* 347, aaa2630. [PubMed: 25636800]
- Liu S, Kwon M, Mannino M, Yang N, Renda F, Khodjakov A, and Pellman D (2018). Nuclear envelope assembly defects link mitotic errors to chromothripsis. *Nature* 561, 551–555. [PubMed: 30232450]
- London N, and Biggins S (2014). Signalling dynamics in the spindle checkpoint response. *Nat. Rev. Mol. Cell Biol.* 15, 736–747. [PubMed: 25303117]
- Ly P, Teitz LS, Kim DH, Shoshani O, Skaletsky H, Fachinetti D, Page DC, and Cleveland DW (2017). Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining. *Nat. Cell Biol.* 19, 68–75. [PubMed: 27918550]
- Ly P, Brunner SF, Shoshani O, Kim DH, Lan W, Pyntikova T, Flanagan AM, Behjati S, Page DC, Campbell PJ, et al. (2019). Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. *Nat. Genet.* 51, 705–715. [PubMed: 30833795]
- Maciejowski J, and Hatch EM (2020). Nuclear Membrane Rupture and Its Consequences. *Annu. Rev. Cell Dev. Biol.* 36, 85–114. [PubMed: 32692592]
- Maciejowski J, Li Y, Bosco N, Campbell PJ, and de Lange T (2015). Chromothripsis and Kataegis Induced by Telomere Crisis. *Cell* 163, 1641–1654. [PubMed: 26687355]
- Maciejowski J, Chatziplis A, Dananberg A, Chu K, Toufektchan E, Klimczak LJ, Gordenin DA, Campbell PJ, and de Lange T (2020). APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis. *Nat. Genet.* 52, 884–890. [PubMed: 32719516]
- Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, Olova N, Sutcliffe H, Rainger JK, Leitch A, et al. (2017). cGAS surveillance of micronuclei links genome instability to innate immunity. *Nature* 548, 461–465. [PubMed: 28738408]
- Mazur DJ, and Perrino FW (2001). Excision of 3' Termini by the Trex1 and TREX2 3' → 5' Exonucleases characterization of the recombinant proteins. *J. Biol. Chem.* 276, 17022–17029. [PubMed: 11279105]
- Nader GPF, Agüera-Gonzalez S, Routet F, Gratia M, Maurin M, Cancila V, Cadart C, Gentili M, Yamada A, Lodillinsky C, et al. (2020). Compromised nuclear envelope integrity drives tumor cell invasion. *bioRxiv.* 10.1101/2020.05.22.110122
- Nunes-Hasler P, Maschalidi S, Lippens C, Castelbou C, Bouvet S, Guido D, Bermont F, Bassoy EY, Page N, Merkler D, et al. (2017). STIM1 promotes migration, phagosomal maturation and antigen cross-presentation in dendritic cells. *Nat. Commun.* 8, 1852. [PubMed: 29176619]
- Petljak M, Alexandrov LB, Brammell JS, Price S, Wedge DC, Grossmann S, Dawson KJ, Ju YS, Iorio F, Tubio J, et al. (2019). Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. *Cell*, 176, 1282–1294.e20. [PubMed: 30849372]
- Raab M, Gentili M, de Belly H, Thiam HR, Vargas P, Jimenez AJ, Lautenschlaeger F, Voituriez R, Lennon-Duménil AM, Manel N, et al. (2016). ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA damage and cell death. *Science* 352, 359–362. [PubMed: 27013426]

- Richards A, van den Maagdenberg AMJM, Jen JC, Kavanagh D, Bertram P, Spitzer D, Liszewski MK, Barilla-LaBarca M-L, Terwindt GM, Kasai Y, et al. (2007). C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. *Nat. Genet* 39, 1068–1070. [PubMed: 17660820]
- Santaguida S, Tighe A, D'Alise AM, Taylor SS, and Musacchio A (2010). Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. *J. Cell Biol* 190, 73–87. [PubMed: 20624901]
- Shimizu N, Kanda T, and Wahl GM (1996). Selective capture of acentric fragments by micronuclei provides a rapid method for purifying extrachromosomally amplified DNA. *Nat. Genet* 12, 65–71. [PubMed: 8528254]
- Simpson SR, Rego SL, Harvey SE, Liu M, Hemphill WO, Venkatadri R, Sharma R, Grayson JM, and Perrino FW (2020). T Cells Produce IFN- $\alpha$  in the TREX1 D18N Model of Lupus-like Autoimmunity. *J. Immunol* 204, 348–359. [PubMed: 31826941]
- van Steensel B, Smogorzewska A, and de Lange T (1998). TRF2 protects human telomeres from end-to-end fusions. *Cell* 92, 401–413. [PubMed: 9476899]
- Stetson DB, Ko JS, Heidmann T, and Medzhitov R (2008). Trex1 prevents cell-intrinsic initiation of autoimmunity. *Cell* 134, 587–598. [PubMed: 18724932]
- Sun L, Wu J, Du F, Chen X, and Chen ZJ (2013). Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* 339, 786–791. [PubMed: 23258413]
- Tice RR, Andrews PW, and Singh NP (1990). The Single Cell Gel Assay: A Sensitive Technique for Evaluating Intercellular Differences in DNA Damage and Repair Sutherland BM, Woodhead AD (eds) DNA Damage and Repair in Human Tissues. Basic Life Sciences, vol 53 Springer.
- Tká J, Xu G, Adhikary H, Young JTF, Gallo D, Escribano-Díaz C, Krietsch J, Orthwein A, Munro M, Sol W, et al. (2016). HELB Is a Feedback Inhibitor of DNA End Resection. *Mol. Cell* 61, 405–418. [PubMed: 26774285]
- Umbreit NT, Zhang C-Z, Lynch LD, Blaine LJ, Cheng AM, Tourdot R, Sun L, Almubarak HF, Judge K, Mitchell TJ, et al. (2020). Mechanisms generating cancer genome complexity from a single cell division error. *Science* 368.
- Vargas JD, Hatch EM, Anderson DJ, and Hetzer MW (2012). Transient nuclear envelope rupturing during interphase in human cancer cells. *Nucleus* 3, 88–100. [PubMed: 22567193]
- Vietri M, Schultz SW, Bellanger A, Jones CM, Petersen LI, Raiborg C, Skarpen E, Pedurupillay CRJ, Kjos I, Kip E, et al. (2020). Unrestrained ESCRT-III drives micronuclear catastrophe and chromosome fragmentation. *Nat. Cell Biol* 22, 856–867. [PubMed: 32601372]
- Volkman HE, Cambier S, Gray EE, and Stetson DB (2019). Tight nuclear tethering of cGAS is essential for preventing autoreactivity. *Elife* 8.
- Willan J, Cleasby AJ, Flores-Rodriguez N, Stefani F, Rinaldo C, Pisciotanni A, Grant E, Woodman P, Bryant HE, and Ciani B (2019). ESCRT-III is necessary for the integrity of the nuclear envelope in micronuclei but is aberrant at ruptured micronuclear envelopes generating damage. *Oncogenesis* 8, 29. [PubMed: 30988276]
- Wolf C, Rapp A, Berndt N, Staroske W, Schuster M, Dobrick-Mattheuer M, Kretschmer S, König N, Kurth T, Wiczorek D, et al. (2016). RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA. *Nat. Commun* 7, 11752. [PubMed: 27230542]
- Xia Y, Ivanovska IL, Zhu K, Smith L, Irianto J, Pfeifer CR, Alvey CM, Ji J, Liu D, Cho S, et al. (2018). Nuclear rupture at sites of high curvature compromises retention of DNA repair factors. *J. Cell Biol* 217, 3796–3808. [PubMed: 30171044]
- Yan N (2017). Immune Diseases Associated with TREX1 and STING Dysfunction. *J. Interferon Cytokine Res* 37, 198–206. [PubMed: 28475463]
- Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, and Lieberman J (2010). The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. *Nat. Immunol* 11, 1005–1013. [PubMed: 20871604]
- Yang H, Wang H, Ren J, Chen Q, and Chen ZJ (2017). cGAS is essential for cellular senescence. *Proc. Natl. Acad. Sci. U. S. A* 114, E4612–E4620. [PubMed: 28533362]


- Young AM, Gunn AL, and Hatch EM (2020). BAF facilitates interphase nuclear membrane repair through recruitment of nuclear transmembrane proteins. *Mol. Biol. Cell* 31, 1551–1560. [PubMed: 32459568]
- Zhang C-Z, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, Meyerson M, and Pellman D (2015). Chromothripsis from DNA damage in micronuclei. *Nature* 522, 179–184. [PubMed: 26017310]
- Zhou W, Whiteley AT, de Oliveira Mann CC, Morehouse BR, Nowak RP, Fischer ES, Gray NS, Mekalanos JJ, and Kranzusch PJ (2018). Structure of the Human cGAS-DNA Complex Reveals Enhanced Control of Immune Surveillance. *Cell* 174, 300–311.e11. [PubMed: 30007416]
- Zierhut C, Yamaguchi N, Paredes M, Luo J-D, Carroll T, and Funabiki H (2019). The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death. *Cell* 178, 302–315.e23. [PubMed: 31299200]

**Highlights**

- TREX1 limits cGAS activation at micronuclei
- TREX1 accesses and degrades micronuclear DNA upon micronuclear envelope rupture
- ER-tethering is critical for TREX1 activity and cGAS regulation at micronuclei
- Disruption of TREX1 ER-tethering may contribute to the etiology of immune diseases




**Figure 1. TREX1 inhibits cGAS activation at MN.** (A) Live-cell imaging of the indicated MCF10A cells expressing H2B-RFP. Insets mark time in minutes since mitotic NE breakdown ( $t = 0$ ). Arrows mark mis-segregating chromosomes. (B) Quantification of cell divisions resulting in the formation of MN or DNA bridges as shown in (A). Mean and s.d. of  $n = 3$  experiments ( $>50$  cells analyzed per experiment) are shown. (C,D) ELISA analysis of cGAMP production in the indicated cells. Mean and s.d. of  $n = 3$  experiments are shown. (E) Immunoblotting for pIRF3(S386), TREX1 and actin in the indicated MCF10A cells. (F) Quantification of pIRF3(S386) relative to corresponding actin signal as shown in (E). Mean and s.d. of  $n = 3$  experiments are shown. (G) Immunofluorescence for pIRF3(S396) in the indicated MCF10A cells. (H) Quantification of pIRF3(S396) foci as shown in (G). Mean and s.d. of  $n = 2$  experiments are shown ( $>250$  cells quantified per replicate).  $P$  values were calculated by Kruskal-Wallis test for multiple comparisons (\*\*\*\* $P < 0.0001$ ). (I) Nanostring expression analysis in the indicated MCF10A cells. ( $n = 1$  experiment). (J) RT-qPCR of *IFNB* and *ISG56* expression in the indicated MCF10A cells. Mean and s.d. of  $n = 3$  experiments are shown. (K) Immunofluorescence for cGAS in the indicated MCF10A cells. (L) cGAS signal intensity with median as in (K) ( $n = 3$  experiments with  $>60$  MN quantified per experiment). Unless otherwise specified all  $P$  values were calculated by one-way ANOVA with Tukey’s multiple comparisons test (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ , ns = not significant). Scale bars = 10  $\mu$ m.



**Figure 2. Purification of cGAS-positive MN.**

(A) Schematic of MN purification. (B) Immunofluorescence for mCherry and GFP in HEK293T + H2B-mCherry + GFP-cGAS cells. Green arrows mark cGAS-positive MN, red arrows mark cGAS-negative MN. Scale bar = 10  $\mu\text{m}$ . (C) Flow profiles of cGAS-negative and cGAS-positive MN isolated by FACS. (D) Immunofluorescence for GFP (cGAS) in the indicated fractions after FACS. Scale bar = 25  $\mu\text{m}$ . (E) Measurement of the area of sorted primary nuclei (PN) and MN sorted by FACS. (F) Quantification of the GFP-cGAS signal intensity as shown in (D). (G) Immunoblotting for the indicated proteins in MN sorted from parental and 3 $\times$ FLAG-TREX1 overexpressing HEK293T cells. (H) Quantification of relative cGAS and TREX1 signals normalized to loading control (SMC1 or histone H3) as shown in (G). Mean and s.d. of  $n = 3$  experiments are shown. All  $P$  values were calculated by one-way ANOVA with Tukey's multiple comparisons test (\*\*\*\*  $P < 0.0001$ , ns = not significant).






**Figure 3. TREX1 localizes to MN after MNE rupture.**


(A) Live-cell imaging of MCF10A cells expressing GFP-TREX1 and H2B-mCherry. Arrows mark MN. (B) Quantification of the cumulative percentage of TREX1-positive MN as shown in (A). Error bars show s.d. of 45 MN quantified across  $n = 3$  experiments. (C) Quantification of the relative fluorescence signal intensities of GFP-TREX1 and H2B-mCherry at MN ( $t = 0$ , initial TREX1 localization) as shown in (A). Relative mean fluorescence intensities and s.d. of 11 MN from  $n = 2$  experiments are shown. (D) Live-cell imaging of MCF10A cells expressing GFP-TREX1, H2B-mCherry and NLS-3 $\times$ mTurquoise2 ( $t = 0$ , MNE rupture). (E) Quantification of the relative fluorescence signal intensities of GFP-TREX1 and NLS-3 $\times$ mTurquoise2 as shown in (D). Mean and s.d. of 15 MN from  $n = 3$  experiments are shown. (F) Immunofluorescence for TREX1 and LSD1 in the indicated cells. Insets show magnified regions. (G) Quantification of the percentage of TREX1-positive ruptured and intact MN as shown in (F). Mean of  $n = 2$  experiments are shown ( $>90$  MN quantified per replicate and cell line). (H) Schematic of full-length TREX1, TREX1 R128A R174A (RA), and TREX1 N (amino acids 2-235 deleted). (I) Immunofluorescence for GFP (TREX1) and H3K9ac in the indicated MCF10A cells. Arrows denote MN. (J) Quantification of TREX1 signal intensity at ruptured (rMN) and intact MN (iMN) relative to TREX1 signal intensity at the ER. Data represent  $>30$  MN quantified from  $n = 3$  experiments. Mean and s.d. are indicated.  $P$  values were calculated by

one-way ANOVA with Tukey's multiple comparisons test (\*\*\*\* $P < 0.0001$ , ns = not significant). All scale bars = 10  $\mu\text{m}$ .



**Figure 4. ER-tethering of TREX1 mediates recruitment to ruptured MN.**


(A) Immunofluorescence for TREX1 and Calreticulin in the indicated cells. Arrows denote intact or ruptured MN. (B) Quantification of TREX1 and Calreticulin signal intensity at MN (Pearson  $r = 0.72$  HeLa;  $r = 0.59$  MCF10A). (C) Live-cell imaging of HeLa cells expressing GFP-TREX1, RFP-KDEL, and NLS-3 $\times$ mTurquoise2. Arrow marks MN. (D) Quantification of the relative fluorescence signal intensities of GFP-TREX1, RFP-KDEL, and NLS-3 $\times$ mTurquoise2 at MN ( $t = 0$  MNE rupture) as shown in (C). Relative mean fluorescence intensities and s.d. are shown ( $n = 19$  MN imaged in cells expressing NLS-3 $\times$ mTurquoise2, GFP-TREX1, RFP-KDEL). (E) Live-cell imaging of HeLa cells expressing GFP-TREX1 and NLS-3 $\times$ mTurquoise2. (F) Quantification of the relative fluorescence signal intensities of GFP-TREX1, ER tracker dye, and NLS-3 $\times$ mTurquoise2. ( $t = 0$  MNE rupture) as shown in (E). Relative mean fluorescence intensities and s.d. are shown ( $n = 28$  MN imaged in cells expressing NLS-3 $\times$ mTurquoise2, GFP-TREX1, and stained with ER tracker). (G) Schematic of full length TREX1, TREX1 C, and TREX1 C-Sec61-TMD. (H,I) Immunofluorescence for GFP (TREX1) and (H) Calreticulin or (I) LSD1 in the indicated cell lines. Arrows mark ruptured MN. (J) Quantification of the percentage of GFP-TREX1-positive ruptured and intact MN as shown in (E). Mean and s.d. of  $n = 3$  experiments are shown ( $>180$  MN quantified per replicate and cell line).  $P$  values were calculated by one-way ANOVA with Tukey's multiple comparisons test (\*\*\*\* $P < 0.0001$ ). All scale bars = 10  $\mu$ m.



**Figure 5. TREX1 degrades micronuclear DNA after MNE rupture.**

(A) Live-cell imaging of the indicated MCF10A cells. Arrows mark MN. (B) Immunofluorescence for RPA32 and LSD1. Arrows mark ruptured MN. (C) Quantification of the percentage of ruptured and intact MN positive for RPA32 foci as shown in (B). Mean and s.d. from  $n = 3$  experiments are shown ( $>200$  MN quantified per experiment and cell line). (D) Immunofluorescence for BrdU and cGAS. Arrows mark ruptured MN. (E) Quantification of the percentage of BrdU-positive ruptured and intact MN as shown in (D). Mean and s.d. from  $n = 3$  experiments are shown ( $>180$  MN quantified per replicate and cell line).  $P$  value was calculated by Student's  $t$ -test ( $***P = 0.0002$ ). (F) Immunoblotting for the indicated proteins in MN sorted from parental and 3 $\times$ FLAG-TREX1 overexpressing HEK293T cells. (G) Quantification of relative RPA32 signal intensity normalized to loading control (SMC1) as shown in (F). Mean and s.d. of  $n = 3$  experiments are shown. (H) Immunofluorescence for RPA32 in the indicated cells. Arrows mark MN. (I) Quantification of the percentage of RPA32-positive MN as shown in (H). Mean and s.d. from  $n = 3$  experiments are shown ( $>220$  MN quantified per replicate and cell line). (J) Immunofluorescence for  $\gamma$ H2AX and LSD1 in the indicated MCF10A cells. Arrows mark ruptured MN. (K) Quantification of the percentage of ruptured and intact MN with detectable  $\gamma$ H2AX foci as shown in (J). Mean and s.d. from  $n = 3$  experiments are shown ( $>180$  MN quantified per replicate and cell line). (L) Representative images of comet assays. (M) Quantification of tail moment in comet assays. (N) Immunofluorescence for RPA32 and LSD1 in parental and APEX1 KO cells. (O) Quantification of RPA32-positive MN in ruptured and intact MN in parental and APEX1 KO cells. (P) Immunofluorescence for RPA32 and LSD1 in MCF10A cells expressing GFP-TREX1 or GFP-TREX1 with various mutations. (Q) Quantification of RPA32-positive MN in ruptured and intact MN in MCF10A cells expressing GFP-TREX1 or GFP-TREX1 with various mutations.

from MN purified from the indicated cells. Scale bars = 25  $\mu\text{m}$ . (M) Quantification of tail moment (% tail DNA x tail length) as shown in (L). Mean and s.d. are shown ( $n = 63-104$ , from  $n = 4$  experiments). (N) Immunofluorescence for RPA32 and LSD1 in the indicated cells. Arrows mark MN. (O) Quantification of the percentage of RPA32-positive ruptured and intact MN as shown in (N). Mean and s.d. from  $n = 3$  experiments are shown ( $>160$  MN quantified per replicate per cell line).  $P$  value was calculated by Student's  $t$ -test ( $*P < 0.05$ ). (P) Immunofluorescence for GFP, RPA32 and LSD1 in indicated cells. Arrows mark ruptured MN. (Q) Quantification of the percentage of RPA32-positive ruptured and intact MN as shown in (P). Mean and s.d. from  $n = 3$  experiments are shown. Unless specified otherwise all  $P$  values were calculated by two-way ANOVA with Sidak's multiple comparisons test ( $****P < 0.0001$ ). All scale bars = 10  $\mu\text{m}$ .



**Figure 6. TREX1 ER-tethering is essential for inhibiting cGAS activation at MN.**

(A) ELISA analysis of cGAMP production in the indicated cells. Mean and s.d. of  $n = 3$  experiments are shown. (B) Nanostring analysis of gene expression in the indicated MCF10A cells ( $n = 3$  experiments). (C) ELISA analysis of cGAMP production in the indicated cells. Mean and s.d. of  $n = 3$  experiments are shown. All  $P$  values were calculated by one-way ANOVA with Tukey's multiple comparisons test (\*\*\*\* $P < 0.0001$ , \*\* $P < 0.01$ , ns = not significant). (D) MCF10A *TREX1* KO cells reconstituted with the indicated GFP-TREX1 constructs were transfected with the indicated ISDs and GFP-TREX1 ISD-association was assessed by immunoblotting.





## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
APE1	abcam	Cat#ab194; RRID:AB_302694
BAF	abcam	Cat#ab129184; RRID:AB_11150422
BrdU	Millipore	Cat#MAB3510; RRID:AB_94897
Calreticulin	Invitrogen	Cat#PA3-900; RRID:AB_325990
cGAS	Cell signaling technology	Cat#15102; RRID:AB_2732795
CHMP2A	ProteinTech	Cat#10477-1-AP; RRID:AB_2079470
dsDNA	Abcam	Cat#ab27156; AB_470907
GFP	Santa Cruz	Cat#sc-9996; RRID:AB_627695
GFP	Invitrogen	Cat#A-11120; AB_221568
H3K9ac	Cell signaling technology	Cat#9649; RRID:AB_823528
Histone H2A	Abcam	Cat#ab18255; RRID:AB_470265
LaminB1	Abcam	Cat#ab16048; RRID:AB_443298
LSD1	Cell signaling technology	Cat#2184; RRID:AB_2070132
mCherry	Abcam	Cat#ab213511; RRID:AB_2814891
pIRF3 (S386)	Abcam	Cat#ab76493; RRID:AB_152383
IRF3 (pS396)	Cell signaling technology	Cat#29047; RRID:AB_2773013
pRPA32 (pT21)	Abcam	Cat#ab109394; RRID:AB_10860648
Rb	BD	Cat#554136; RRID:AB_395259
RPA32	Abcam	Cat#ab2175; RRID:AB_302873
SMC1	Bethyl laboratories	Cat#A300-055A; RRID:AB_2192467
TREX1	Abcam	Cat#ab185228
TREX1	Santa Cruz	Cat#sc-271870; RRID:AB_10708266
TRF2 (Rb. #647)	de Lange Lab	N/A
$\gamma$ H2AX	Millipore	Cat#056361
$\alpha$ -tubulin	Abcam	Cat#ab7291; RRID:AB_2241126
$\beta$ -actin (m)	Abcam	Cat#ab8224; RRID:AB_449644
$\beta$ -actin (rb)	Abcam	Cat#ab8227; RRID:AB_2305186
$\gamma$ -tubulin	Abcam	Cat#ab11316; RRID:AB_297920
Goat anti-Mouse IgG Alexa Fluor 488	Invitrogen	Cat#A11001; RRID:AB_2534069
Goat anti-Rabbit IgG Alexa Fluor 488	Invitrogen	Cat#A11034; RRID:AB_2576217
Goat anti-Mouse IgG Alexa Fluor Plus 555	Invitrogen	Cat#A32727; RRID:AB_2633276
Goat anti-Rabbit IgG Alexa Fluor Plus 555	Invitrogen	Cat#A32732; RRID:AB_2633281
Goat anti-Mouse IgG Alexa Fluor 647	Invitrogen	Cat#A21236; RRID:AB_2535805
Goat anti-Rabbit IgG Alexa Fluor 647	Invitrogen	Cat#A21245; RRID:AB_2535813
Goat anti-Mouse IgG HRP	Thermo Fisher Scientific	Cat#31432; RRID:AB_228302
Donkey anti-rabbit IgG HRP	SouthernBiotech	Cat#6441-05; RRID:AB_2796374

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Goat anti-Mouse IgG Alexa Fluor Plus 680	Invitrogen	Cat#A32729; RRID:AB_2633278
Goat anti-Rabbit IgG Alexa Fluor Plus 800	Invitrogen	Cat#A32735; RRID:AB_2633284
Bacterial and Virus Strains		
Biological Samples		
Chemicals, Peptides, and Recombinant Proteins		
Aqua Hold Pap Pen 2	Thermo Fisher Scientific	Cat#23-769-533
Cholera Toxin	Sigma-Aldrich	Cat#C8052-2mg
Cytochalasin B	Cayman Chemical Company	Cat#11328
Cytofunnel	Shandon	Cat#5991039
Dynabeads MyOne Streptavidin T1	invitrogen	Cat#65601
Dynabeads Protein G	invitrogen	Cat#10030
ER tracker	Thermo Fisher Scientific	Cat#E34250
Fugene HD Transfection Reagent	Promega	Cat#E2311
Glass bottom dishes	Cellvis	Cat#D35-20-1.5-N
Glass bottom dishes (4 chamber)	Cellvis	Cat#D35C4-20-1.5-N
Horse Serum	Thermo Fisher Scientific	Cat#26050088
human EGF	Sigma-Aldrich	Cat#E9644-.2mg
Hydroxyurea (HU)	Sigma-Aldrich	Cat#H8627-5G
Insulin	Sigma-Aldrich	Cat#I9278-5ml
ISD (Interferon Stimulatory DNA)	Invivogen	Cat#NC0432595
Lipofectamine 3000	Thermo Fisher Scientific	Cat#L3000075
Minitrainer 40 $\mu$ m	pluriSelect	Cat#43-10040-46
Nitrocellulose membrane	Thermo Fisher Scientific	Cat#10600002
Novex WedgeWell Tris Glycine Mini gels	Thermo Fisher Scientific	Cat#XP08160BOX
Odyssey Blocking Buffer (TBS)	LI-COR Biosciences	Cat#927-50000
ProLong Gold antifade reagent	Invitrogen	Cat#P36934
Protease Inhibitor Tablets, EDTA-free	Thermo Scientific	Cat#A32965
Quick-RNA Miniprep Kit	Zymo	Cat#R1054
Reversine	Cayman Chemical Company	Cat#10004412
SYBR Green Master Mix	Applied Biosystems	Cat#A25742
Spermidine	Thermo Fisher Scientific	Cat#AC132740010
Spermine	Thermo Fisher Scientific	Cat#AC132750010
SuperScript IV First-Strand Synthesis System	Invitrogen	Cat#18091200
Critical Commercial Assays		
2'3'-Cyclic GAMP Direct EIA Kit	Arbor Assays	Cat#K067-H5
BCA Protein Assay	Thermo Fisher Scientific	Cat#23227
nCounter Human Inflammation V2 Panel	NanoString Technologies	Cat#XT-CSO-HIN2-12

REAGENT or RESOURCE	SOURCE	IDENTIFIER
custom nCounter gene expression code set, see Table S1	NanoString Technologies	N/A
Deposited Data		
Raw Western blot, imaging and gene analysis data	this paper; Mendeley Data	<a href="http://dx.doi.org/10.17632/d8p53cv3ry.1">http://dx.doi.org/10.17632/d8p53cv3ry.1</a>
Experimental Models: Cell Lines		
BT474	Michael Stratton Lab; Petljak et al., 2019	N/A
BT549	Hironori Funabiki Lab; Zierhut et al., 2019	N/A
CAL-51	Hironori Funabiki Lab; Zierhut et al., 2019	N/A
HCC1143	Hironori Funabiki Lab; Zierhut et al., 2019	N/A
HEK293T	ATCC	Cat#ACS-4500
HEK293T H2B-mCherry #4	this paper	cET1
HEK293T H2B-mCherry #4 GFP-cGAS #1	this paper	cET2
HEK293T H2B-mCherry #4 GFP-cGAS #1 3×FLAG-TREX1 #1	this paper	cET3
HEK293T GFP-cGAS 3xmCherry-NLS	this paper	cET4
HeLa	ATCC	Cat#CRM-CCL-2
HeLa (iCAS9) GFP-TREX1 NLS-3xmTurq	this paper	cPvM1
HeLa (iCAS9) GFP-TREX1 NLS-3xmTurq RFP-KDEL	this paper	cPvM2
HT1080	ATCC	Cat#CCL-121
HT1080 <i>TREX1</i> KO	this paper	cJM1
M2p1 (MCF10A <i>TP53</i> <sup>-/-</sup> doxi::TRF2-DN)	this paper	cLM1
M2p1 H2B-mCherry GFP-cGAS	this paper	cJM2
M2p1 H2B-mCherry GFP-BAF	this paper	cJM3
M2p1 H2B-mCherry GFP-LaminB1	this paper	cJM4
M2p1 H2B-mCherry GFP-TREX1	this paper	cJM5
M2p1 <i>TREX1</i> KO #1	this paper	cLM2
M2p1 <i>TREX1</i> KO #1 H2B-mCherry GFP-cGAS	this paper	cJM6
M2p1 <i>TREX1</i> KO #1 H2B-mCherry GFP-BAF	this paper	cJM7
M2p1 <i>TREX1</i> KO #2	this paper	cLM3
M2p1 <i>TREX1</i> KO #2 H2B-mCherry GFP-cGAS	this paper	cJM8
M2p1 <i>TREX1</i> KO #2 H2B-mCherry GFP-BAF	this paper	cJM9
M2p1 <i>TREX1</i> KO #2 H2B-mCherry GFP-LaminB1	this paper	cJM10
M2p1 <i>TREX1</i> KO <i>CGAS</i> KO	this paper	cLM4
MCF10A	Maria Jasin lab	N/A
MCF10A H2B-mCherry	this paper	cJM11
MCF10A H2B-mCherry GFP-RPA70 NLS-3xmTurq	this paper	cJM12
MCF10A Turq-3× FLAG-TREX1	this paper	cLM5

REAGENT or RESOURCE	SOURCE	IDENTIFIER
MCF10A Turq-3× FLAG-TREX1-D18N	this paper	cLM6
MCF10A GFP-cGAS	this paper	cJM13
MCF10A <i>TREX1</i> KO #1	this paper	cJM14
MCF10A <i>TREX1</i> KO #1 H2B-mCherry	this paper	cJM15
MCF10A <i>TREX1</i> KO #1 H2B-mCherry GFP-TREX1	this paper	cJM16
MCF10A <i>TREX1</i> KO #1 H2B-mCherry GFP-TREX1 NLS-3xmTurq	this paper	cJM17
MCF10A <i>TREX1</i> KO #1 H2B-mCherry GFP-TREX1 cGAS-mTurquoise2	this paper	cJM18
MCF10A <i>TREX1</i> KO #1 GFP-TREX1	this paper	cLM7
MCF10A <i>TREX1</i> KO #1 GFP-TREX1 H2B-iRFP670	this paper	cLM8
MCF10A <i>TREX1</i> KO #1 GFP-TREX1 H2B-iRFP670 NLS-3xmTurq	this paper	cPvM3
MCF10A <i>TREX1</i> KO #1 GFP-TREX1 H2B-iRFP670 NLS-3xmTurq RFP-KDEL	this paper	cPvM4
MCF10A <i>TREX1</i> KO #1 GFP-TREX1- C (aa1-235)	this paper	cLM9
MCF10A <i>TREX1</i> KO #1 GFP-TREX1- C H2B-iRFP670	this paper	cLM10
MCF10A <i>TREX1</i> KO #1 GFP-TREX1- C-SEC61-TMD	this paper	cLM11
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-D18N	this paper	cLM12
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-R128A R174	this paper	cLM13
MCF10A <i>TREX1</i> KO #1 GFP-TREX1- N (aa236-314)	this paper	cLM14
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-309*	this paper	cLM15
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-V235fs	this paper	cLM16
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-D272fs	this paper	cLM17
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-L287fs	this paper	cLM18
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-P290L	this paper	cLM19
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-Y305C	this paper	cLM20
MCF10A <i>TREX1</i> KO #1 GFP-TREX1-G306A	this paper	cLM21
MCF10A <i>TREX1</i> KO #1 Turq-3× FLAG-TREX1	this paper	cLM22
MCF10A <i>TREX1</i> KO #1 Turq-3× FLAG-TREX1-D18N	this paper	cLM23
MCF10A <i>TREX1</i> KO #1 GFP-cGAS	this paper	cJM19
MCF10A <i>TREX1</i> KO #2	this paper	cJM20
MCF10A <i>TREX1</i> KO #2 H2B-mCherry	this paper	cJM21
MCF10A <i>TREX1</i> KO #2 GFP-cGAS	this paper	cJM22
MCF10A <i>TREX1</i> hypomorph	this paper	cJM23
MCF10A <i>TREX1</i> KO #1 <i>MB21D1</i> ( <i>cGAS</i> ) KO	this paper	cLM24
MDA-MB-453	Michael Stratton lab; Petljak et al., 2019	N/A
Phoenix	Titia de Lange lab	N/A
RPE1 hTERT	ATCC	Cat#CRL-4000

REAGENT or RESOURCE	SOURCE	IDENTIFIER
RPE1 hTERT <i>TREX1</i> KO	this paper	cJM24
T2p1 (RPE1 hTERT <i>TP53</i> <sup>-/-</sup> doxi::TRF2-DN)	Titia de Lange lab	N/A
T2p1 <i>APEX1</i> KO	Titia de Lange lab	N/A
U2OS	ATCC	Cat#HTB-96
Experimental Models: Organisms/Strains		
Oligonucleotides		
ISD (biotinylated or naked for pulldown experiments); (TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA)	IDT	N/A
IFN $\beta$ F for qPCR (AAACTCATGAGCAGTCTGCA)	Carr et al., 2017	N/A
IFN $\beta$ R for qPCR (AGGAGATCTTCAGTTTCGGAGG)	Carr et al., 2017	N/A
ISG56 F for qPCR (AAGGCAGGCTGTCCGCTTA)	Diner et al., 2015	N/A
ISG56 R for qPCR (TCCTGTCCTTCATCTGAAGCT)	Diner et al., 2015	N/A
actin F for qPCR (CAACCGCGAGAAGATGAC)	Bakhoun et al., 2018	N/A
actin R for qPCR (ATCACGATGCCAGTGGTACG)	Bakhoun et al., 2018	N/A
hTREX1; guide RNA #1 (TCAACGCTTCGATGACAACC)	this paper	N/A
hTREX1; guide RNA #2 (GCATCTACACCCGCTGTAC)	this paper	N/A
hTREX1; guide RNA #3 (CCACTGGAACAACCAACCTA)	this paper	N/A
hCGAS; guide RNA #2 (GGCCCCATTCTCGTACGGA)	this paper	N/A
hCGAS; guide RNA #3 (GTTCGGCCCCGCCAGGAAGT)	this paper	N/A
TP53; guide RNA (GGCAGCTACGGTTCCGTC)	this paper	N/A
Recombinant DNA		
pTK puro HA-GFP-cGAS	gift from Zhijian Chen	N/A
pQCXIZ 3 $\times$ FLAG-TREX1	this paper	Addgene #164243
pQCXIB H2B-mCherry	this paper	Addgene #164244
pQCXIP GFP-TREX1	this paper	Addgene #164245
pQCXIP NLS-3 $\times$ mTurquoise2	this paper	Addgene #164246
pLenti CMV GFP Neo	Campeau et al., 2009	Addgene #17447
pLenti CMV GFP Blast	Campeau et al., 2009	Addgene #17445
pLenti CMV GFP Puro	Campeau et al., 2009	Addgene #17448
pLenti 3xmCherry-NLS	gift from Emily Hatch	N/A
pLenti CMV GFP-TREX1 BLAST	this paper	Addgene #164228
pLenti CMV GFP-TREX1- C BLAST	this paper	Addgene #164229
pLenti CMV GFP-TREX1- C-SEC61-TMB BLAST	this paper	Addgene #164230
pQCXIP GFP-RPA70	this paper	Addgene #164231



REAGENT or RESOURCE	SOURCE	IDENTIFIER
pQCXIZ Turq-3×FLAG-TREX1	this paper	Addgene #164232
pQCXIZ Turq-3×FLAG-TREX1 D18N	this paper	Addgene #164233
pLenti CMV GFP-TREX1 D18N BLAST	this paper	Addgene #164225
pLenti CMV GFP-TREX1 R128A R174 BLAST	this paper	Addgene #164234
pLenti CMV GFP-TREX1 N BLAST	this paper	Addgene #164235
pLenti CMV GFP-TREX1 309* BLAST	this paper	Addgene #164242
pLenti CMV GFP-TREX1 V235fs BLAST	this paper	Addgene #164236
pLenti CMV GFP-TREX1D272fs BLAST	this paper	Addgene #164237
pLenti CMV GFP-TREX1 L287fs BLAST	this paper	Addgene #164238
pLenti CMV GFP-TREX1 P290L BLAST	this paper	Addgene #164239
pLenti CMV GFP-TREX1 Y305C BLAST	this paper	Addgene #164240
pLenti CMV GFP-TREX1 G306A BLAST	this paper	Addgene #164241
pMaxGFP	Lonza	Cat#V4SC-9096
pQCXIZ cGAS-mTurquoise2	this paper	Addgene #164247
pLentiPGK DEST H2B-iRFP670	Kudo et al., 2018	Addgene #90237
pQCXIP GFP-BAF	this paper	Addgene #164248
pQCXIP GFP-LmnB1	this paper	Addgene #164249
pU6 TREX1-g1 Cas9-T2A-mCherry	this paper	Addgene #164250
pU6 sgTREX1-g2 Cas9-T2A-mCherry	this paper	Addgene #164251
pU6 sgTREX1-g3 Cas9-T2A-mCherry	this paper	Addgene #164252
pU6 cGAS-g2 Cas9-T2A-mCherry	this paper	Addgene #164253
pU6 cGAS-g3 Cas9-T2A-mCherry	this paper	Addgene #164254
pU6 p53-gRNA Cas9-T2A-mCherry	this paper	Addgene #164256
pHP138-FLAG-TRF2- B M	this paper	Addgene #164255
p2K7 bsd-UBI-tagRFP-KDEL	Nunes-Hasler et al., 2017	Addgene #114179
psPAX2	gift from Didier Trono	Addgene #12260
pMD2.G	gift from Didier Trono	Addgene #12259
Software and Algorithms		
Other		